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ABSTRACT 
Alison M. McGuire: Metabolomic Studies of Saliva in Gingivitis and Periodontitis 
(Under the direction of Steven Offenbacher) 
The aim of this study was to conduct metabolomic analysis of saliva during 3-week 
induction and 4-week resolution of stent-induced, biofilm overgrowth (SIBO) in humans to 
elucidate an association between changes in clinical disease and the salivary metabolome. 
Five periodontal disease classifications were developed using probing depths and 
bleeding on probing. SIBO was induced in 50 subjects for 21 days followed by oral hygiene 
instruction for 28 days. Clinical indices and unstimulated saliva were collected weekly during 
induction and biweekly during resolution. Samples were analyzed using metabolomic profiling 
(liquid and gas chromatography mass spectrometry, Metabolon Inc).  
SIBO was associated with marked, but reversible, increases in clinical indices. 281 
metabolites were identified using metabolomic profiling. Eight metabolites demonstrated 
significant changes including seven in the amino acid super-pathway (threonine, N-acetylserine, 
serine, 5-oxoproline, histidine, glutamate and erythronate). 
Analysis of the salivary metabolome may provide new mechanistic insights for 
periodontal disease progression.  
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CHAPTER 1: INTRODUCTION 
Periodontal disease is a heterogeneous group of inflammatory conditions that affect 
tooth-supporting tissues and is broadly grouped into two major categories: gingivitis and 
periodontitis. Gingivitis is reversible and limited to superficial gingival tissues; periodontitis is 
non-reversible and features tissue destruction extending into the periodontal ligament and 
alveolar bone. Animal studies indicate that gingivitis is a precursor to periodontitis (Heijl, Rifkin, 
& Zander, 1976), however, human population studies have clearly shown that not all individuals 
with gingivitis linearly proceed to periodontitis (Löe, Anerud, Boysen, & Morrison, 1986; 
Socransky, Haffajee, Goodson, & Lindhe, 1984). 
Estimations from NHANES III data suggest that approximately half (47.2%) of the US 
population has periodontal disease (Eke et al., 2012). Underestimations in previously reported 
periodontal disease prevalence may be due to inconsistent definitions of periodontal disease. For 
example, applying a threshold of 1mm CAL results in a prevalence of 99% while applying a 
threshold of greater than 7 mm CAL results in a prevalence of 7% (Albandar, Brunelle, & 
Kingman, 1999). Furthermore, use of partial mouth examinations such as the Ramfjord’s 
Periodontal Disease Index (Ramfjord, 1967) may have led to underestimations in NHANES 
survey studies by 50% (Albandar, 2011). 
There is a substantial body of literature published within the last 10 years that 
demonstrates associations between periodontal disease and a myriad of systemic diseases 
including diabetes, cardiovascular disease, stroke, kidney disease, and adverse pregnancy 
outcomes (Arce et al., 2010; Southerland et al., 2012). These associations have drawn the 
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attention of the medical field which has resulted in translational interdisciplinary research 
opportunities between medicine and dentistry (Williams & Offenbacher, 2000). 
Periodontal disease is a multifactorial disease that is associated with several risk and 
susceptibility factors (Page & Kornman, 1997). Bacterial biofilm has historically been cited as 
the primary etiological factor for periodontal disease (Löe, Theilade, & Jensen, 1965), however, 
the amount of plaque does not necessarily correlate with periodontal disease severity 
(Offenbacher, 1996). Data from cohort studies indicate that a subset of individuals appear to 
exhibit a more pronounced host response to bacterial biofilm as compared to others who fail to 
respond (Offenbacher, Collins, & Arnold, 1993). Trombelli et al. (2004) first identified “high 
responders” and “low responders” in a randomized, split-mouth, localized experimental 
gingivitis model (Trombelli et al., 2004). These two groups were defined by upper and lower 
quartiles of GCF volume. During experimental gingivitis, “high responders“ demonstrated a 
statistically significant increase in GI, angulated bleeding score, and GCF volume but not plaque 
index and cumulative plaque exposure when compared to “low responders”. Evidence of this 
phenomenon was first published almost 50 years ago by Löe et al. (1965) in his classic 
experimental gingivitis study (Löe et al., 1965). Subjects refrained from daily tooth cleaning for 
three weeks to induce gingivitis. Using a clinical index (GI), three subjects developed gingivitis 
within 10 days (“high responders”) whereas nine subjects developed gingivitis between 15-21 
days (“low responders”). Differences in host susceptibility to gingivitis and periodontal disease 
may be traced to inter-individual differences in environmental exposures or genetic risk factors. 
In fact, genetic risk factors have been shown to account for approximately 50% of inter-
individual variability in the expression of periodontal disease (Michalowicz et al., 2000). 
Observational studies suggest that a risk for advanced periodontitis may be elevated in patients 
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with certain genetic biomarkers or polymorphisms (interleukin-1β) however the risk conferred 
by these markers are not consistent among different populations (Kinane & Hart, 2003). In fact, 
Papapanou et al. (2004) conducted a pilot study evaluating gene expression signatures in gingival 
tissues obtained from two subsets of periodontal disease patients: chronic and aggressive. This 
group concluded that gene expression techniques may be useful in the identification of different 
subclasses of periodontal diseases and better allow clinicians to distinguish health from disease 
(Papapanou et al., 2004). Collectively, these studies provide evidence for the potential utility of 
biochemical mediators for periodontal diagnosis.  
The intent of this study is to elucidate the association between clinical disease status and 
the salivary metabolome by conducting metabolomic analysis on saliva from 50 subjects with 
periodontal health, gingivitis and three stages of periodontal disease. We hypothesize that 
metabolomic signatures exist for five disease categories (health, gingivitis, mild, moderate and 
severe periodontitis) which may be applied to novel salivary diagnostic tests. As a secondary 
goal, we were interested in identifying new candidate biomarkers within saliva, which co-vary 
with the changes in clinical status. 
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CHAPTER 2: LITERATURE REVIEW 
Section 2.1: Oral fluids 
Oral fluids are composed predominantly of salivary gland secretions but also variable 
amounts of bronchial and nasal secretions, gingival epithelial cells, food debris, and GCF 
products including serum transudate, microbial, and host products (Kaufman & Lamster, 2002; 
Offenbacher et al., 2010). Inflammatory mediators in GCF have been evaluated as potential 
diagnostic markers for periodontal disease activity and progression. Offenbacher et al. (2007) 
defined BGI categories based on PD and BOP that were validated by multivariate models using 
clinical, microbial, inflammatory, and host-response data (Offenbacher et al., 2007). This 
classification was developed to investigate the underlying biology since it uses PD and BOP 
rather than CAL, which also represents past disease. Offenbacher et al. (2010) conducted an 
experimental gingivitis study using the SIBO model with subjects diagnosed with gingivitis and 
applied immunoadsorbant bead suspension array multiplexing tools to simultaneously analyze 33 
inflammatory mediators within each GCF sample to evaluate changes in GCF composition over 
time (Offenbacher et al., 2010). Gingivitis induction was associated with a significant 2.6-fold 
increase in IL-1β, 3.1-fold increase in IL-1α and significant decreases in select MMP’s and 
chemokines (including IL-8, MIP-1β, ENA-78, MCP-1, and RANTES) that returned to baseline 
values following resolution of experimental gingivitis. Increases in IL-1β and IL-1α during 
gingivitis induction have been described previously (Heasman, Collins, & Offenbacher, 1993; 
Offenbacher et al., 2007). Decreased chemokines may represent increased degradation in the 
sulcus or a shift in chemokine compartmentalization between tissues and GCF. Decreases in the 
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abovementioned chemokines, which are chemotactic for leukocytes, suggests that experimental 
gingivitis induces a transient, but reversible suppression of chemotaxis. This study identified IL-
1β, IL-1α, and select MMP’s and chemokines as potential candidate biomarkers for gingivitis 
induction within the GCF.  
Section 2.2: Advancements in molecular biology technologies 
Due to advancements in molecular biology and, in particular, high-throughput 
technologies, systems biology has emerged in the last decade to evaluate biological systems at 
the level of the genome, transcriptome, proteome, glycome, metabolome, and lipidome which 
have been termed genomics, transcriptomics, proteomics, glycomics, metabolomics, and 
lipidomics respectively (Wu, Zhao, Wang, Zhou, & Chen, 2011). Gingival transcriptome 
patterns during induction and resolution of experimental gingivitis were described by 
Offenbacher et al. (2009) using the SIBO model (Offenbacher et al., 2009). Briefly, gingival 
biopsy samples were collected from 14 subjects at different sites within each subject at baseline 
(Day 0), peak of gingivitis (Day 28), and resolution (Day 35) and processed using whole-
transcriptome gene-expression arrays. During induction, there was a significant transient increase 
in expression levels of transcripts that code for inflammatory cytokines including in IL-1β, IL-
1α, IL-8, RANTES, CSF3, and SOD2 and a decreased expression of IL-10, ITAC, MMP-10, and 
BD-2. 
 
Section 2.3: Metabolomics 
Overview 
Metabolomics is the study of small molecules in biological systems including amino 
acids, peptides, carbohydrates, fatty acids, metabolites, xenobiotics, and exogenous chemical 
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agents (Lawton et al., 2008; Ryals, Lawton, Stevens, & Milburn, 2007). The goal of 
metabolomics is to characterize the metabolic state of a subject via extraction, identification, and 
quantification of all small molecule compounds from a biological sample (Ryals et al., 2007). 
There are advantages of metabolomics over other technologies such as functional genomics, 
transcriptomics, and proteomics. For example, metabolomics provides a biochemical signature 
that includes the effects of genetics, lifestyle, diet, and environmental factors in an individual 
(Ryals et al., 2007). To date, blood, urine, gingival crevicular fluid, saliva, amniotic fluid, 
cerebrospinal fluid, tissues, cell cultures, and plants have been analyzed by metabolomic 
profiling (Ryals et al., 2007). This is a rapidly evolving technology that has been used 
increasingly in drug development and diagnosis of systemic disease (Lawton et al., 2008; Morris 
& Watkins, 2005). For example, this technology has been applied to cardiovascular disease and 
diabetes research (Dunn, Goodacre, Neyses, & Mamas, 2011). It has also been used to 
investigate diagnostic markers for psychological diseases such as depression (Paige, 2007). 
Analysis of biological metabolites for disease diagnosis and monitoring of disease status is not 
novel. For example, blood glucose and cholesterol levels have been used for decades in the 
diagnosis and disease monitoring for diabetes and heart disease respectively. However, 
advancements in technology have allowed for analysis of a much wider variety of metabolites in 
a given sample (Lawton et al., 2008).  
 
Metabolomic profiling: Technology 
Metabolomic profiling includes integration of targeted metabolomic analysis and non-
targeted metabolomic analysis. Targeted metabolomic analysis provides absolute concentrations 
of a small number of known metabolites (Lawton et al., 2008); non-targeted metabolomic 
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profiling provides a relative concentration of a large number of small molecules, known and 
unknown, in a biological sample that permits a broader examination of metabolism (Sha et al., 
2010). Both non-targeted and targeted analyses apply LC/MS and GC/MS. Briefly, metabolites 
extracted from a sample are identified by matching the ion’s chromatographic retention index 
and mass spectral fragmentation signatures with a reference library. For molecules not found in 
the reference library, new library entries are added (Barnes et al., 2009). Quality control is 
essential for several reasons. First, metabolites in biological systems are found in widely varying 
concentrations with different molecular size, functional moieties, lipophilicity, volatility, or other 
physicochemical parameters from which they must be extracted while maintaining their 
structural integrity and relative abundances (Fiehn et al., 2008). Secondly, some compounds, 
such as ATP, ADP, NADH and NADPH are susceptible to oxygen degradation during sample 
preparation. Other compounds, such as sugar phosphates, cysteine and ascorbate are prone to 
degradation by residual enzymatic activity, heat and oxidation (Fiehn et al., 2008). To overcome 
these challenges, quality control samples, including internal standards and endogenous 
biochemicals, are analyzed alone and in conjunction with the samples to measure variation 
between experiments (Lawton et al., 2008). Some variation is acceptable and is due to deviation 
in sample processing, instrument or data processing (Dunn, Wilson, Nicholls, & Broadhurst, 
2012). Extended details of methods are included in Appendix 3.1.1. 
 
Metabolomic profiling: Developing metabolomic signatures in GCF 
Inflammatory biomarkers within oral fluids have been evaluated as a potential diagnostic 
aid for periodontal disease (Barnes et al., 2009). These biomarkers cover a range of biological 
processes that would provide insight as to the presence, absence, and severity of disease and 
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would allow for the development of diagnostic tests. Barnes et al. (2009) applied metabolomic 
profiling to GCF samples collected from healthy, gingivitis, and periodontitis sites in humans via 
LC/MS and GC/MS and identified metabolomic signatures associated with host-bacterial 
interactions (Barnes et al., 2009). Of the 228 metabolites detected, 53 metabolites (23%) 
demonstrated significant differences between subjects with gingival health, gingivitis, and 
periodontitis defined as sites with PD≤3mm, absent BOP; PD≤3mm, BOP present; and 
PD≥5mm, BOP present, respectively after correcting for multiple comparisons (FDR, q < 0.05). 
Most metabolites with altered concentrations at gingivitis sites demonstrated intermediate levels 
between health and periodontitis, which suggests that metabolomic changes are on a continuum. 
Inosine, hypoxanthine, xanthine, guanosine, and guanine were upregulated at the disease sites 
which indicated accelerated metabolic flux of the purine degradation pathway. In accordance 
with these changes, oxygen levels were depleted and reactive oxygen species were elevated by 
xanthine oxidase. Levels of anti-oxidants including reduced and oxidized glutathione, ascorbic 
acid, and uric acid were reduced. These findings suggested an acceleration of reactive oxygen 
species that have been shown to be involved in the pathogenesis of other diseases such as 
cardiovascular disease, ischemic-reperfusion injury, diabetes, hypertension and inflammatory 
disease (Ren, Zhang, Cui, & Mu, 2013). Levels of putrescine and cadaverine, which are the end-
products of amino acid degradation, were also upregulated by disease. The authors suggested 
that host tissues upregulate the purine degradation pathway as a defense mechanism against 
oxidant-sensitive bacterial pathogens (Barnes et al., 2009; Stevens et al., 2000). In a follow-up 
study, Barnes et al. (2010) evaluated the effect of triclosan-containing dentifrice on the 
metabolomic profile of subjects with gingivitis and demonstrated decreased levels of inosine, 
9 
 
lycine, putrescine, and xanthine as early as one week after implementing the triclosan-containing 
dentifrice (Barnes, 2010). 
 
Metabolomic profiling: Developing metabolomic signatures in saliva 
These mediators are detectable in saliva, albeit at a much lower concentration, which 
opens the possibility for a salivary diagnostic to monitor periodontal status. Barnes et al. (2011) 
conducted a study evaluating salivary metabolites in human subjects with periodontal health and 
periodontitis. A total of 68 unstimulated saliva samples were collected from 34 periodontally 
healthy and 34 periodontitis subjects. Of the 390 metabolites that were detected, seven 
metabolites demonstrated significant differences between subjects with periodontal health and 
periodontitis (FDR, q<0.05). Five of the seven metabolites were derived from four different 
superfamilies (leucylisoleucine from the dipeptide superfamily, mannose and glucose from the 
carbohydrate superfamily, arachidonate from the lipid superfamily, and allantoin from the 
nucleotide superfamily) while two were previously unnamed. Metabolites from several pathways 
demonstrated trending changes (t-test, p<0.05) including elevated mono- and oligosaccharides, 
dipeptides, products of glycerophopholipid and triacylglycerol degradation including fatty acids 
arachidonate and docosapentaenoate, and nucleotides. This publication was the first to report on 
metabolomic profiling of saliva and suggested that a number of different metabolites could be 
investigated as candidate biomarkers for a salivary diagnostic tool. Integrating metabolomic 
profiles of the GCF and saliva may provide a comprehensive biochemical basis for 
understanding the pathogenesis of periodontal disease and limit the number of candidate 
biomarkers for a diagnostic aid (Barnes et al., 2011).
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CHAPTER 3: MANUSCRIPT 
Section 3.1: Introduction 
Human saliva contains salivary gland secretions but also variable amounts of bronchial and 
nasal secretions, gingival epithelial cells, food debris, and GCF products; including serum 
transudate, microbial, and host products (Kaufman & Lamster, 2002; Offenbacher et al., 2010). 
In the last decade, the application of systems biology has been used to evaluate biological 
systems at the level of the genome, transcriptome, proteome, glycome, metabolome, and 
lipidome (Wu, Zhao, Wang, Zhou, & Chen, 2011). Recently, the application of whole-
transcriptome gene-expression arrays has been used to characterize gingival transcriptome 
patterns in gingival tissue (using gingival biopsies) during induction and resolution of 
experimental gingivitis using the SIBO model (Offenbacher et al., 2009). During induction, a 
significant transient increase in expression levels of transcripts that code for inflammatory 
cytokines including in IL-1β, IL-1α, IL-8, RANTES, CSF3, and SOD2 and a decreased 
expression of IL-10, ITAC, MMP-10, and BD-2 was noted. For ease of collection, these 
technologies have been applied to GCF and saliva.  
Metabolomics is the study of small molecules in biological systems including amino 
acids, peptides, carbohydrates, fatty acids, metabolites, xenobiotics, exogenous chemical agents 
(Lawton et al., 2008; Ryals, Lawton, Stevens, & Milburn, 2007). Barnes et al. (2009) applied 
metabolomic profiling to GCF samples collected from healthy, gingivitis, and periodontitis sites 
in humans via LC/MS and GC/MS and identified metabolomic signatures associated with host-
bacterial interactions (Barnes et al., 2009). Of the 228 metabolites detected, 23% demonstrated 
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significant differences between subjects with gingival health, gingivitis, and periodontitis. This 
study showed accelerated metabolic flux of the purine degradation pathway, depletion of oxygen 
levels, elevated reactive oxygen species and reduced levels of anti-oxidants (Barnes et al., 2009). 
Additionally, metabolites from the amino acid super-family were increased while metabolites 
from the glutathione pathway were reduced (Barnes et al., 2009). In the first publication to report 
on metabolomic profiling of saliva, Barnes et al. (2011) applied metabolomics to saliva samples 
collected from human subjects with periodontal health and periodontitis. Among the 390 
metabolites detected, 0.02% demonstrated significant differences between subjects with 
periodontal health and periodontitis.  The data indicated changes in biochemicals from several 
different pathways including dipeptides, carbohydrates, lipids and nucleotides which suggested 
that a number of different metabolites could be investigated as candidate biomarkers for a 
salivary diagnostic tool (Barnes et al., 2011). The experimental gingivitis model has been applied 
many times since it was first introduced in the landmark study by Löe et al. (Löe et al., 1965). 
This model has been adapted to include the use of intra-oral stents to be worn only during routine 
oral hygiene measures that cover selected teeth (Burrell & Walters, 2008) to limit the extent of 
gingival inflammation to selected posterior regions of the mouth. In this study, we applied the 
SIBO model in conjunction with metabolomic profiling from human saliva samples to elucidate 
the association between clinical disease status and the salivary metabolome. This was a 
hypothesis-generating experiment with the goal of identifying metabolomic signatures in five 
disease categories (health, gingivitis, mild, moderate and severe periodontitis). As a secondary 
goal,  we were interested in identifying new candidate biomarkers within saliva, which co-vary 
with the changes in clinical status.  
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Section 3.2: Materials and Methods 
Clinical study design and patient enrollment 
This study design represents a modification of the original experimental gingivitis study 
as described by Löe et al.(Löe et al., 1965). We recruited and enrolled subjects who were 
systemically healthy with periodontal diagnoses of health, gingivitis, mild, moderate or severe 
periodontitis in this study conducted at the UNC Center for Oral and Systemic Diseases. The 
study design included a 2-week hygiene phase, a 3-week induction phase using two stents and a 
4-week resolution phase to reinstitute oral hygiene and reverse gingival inflammation. The 
protocol and informed consent were approved by the Institutional Review Board at UNC Chapel 
Hill. 175 subjects (115 females and 60 males; aged 19-68 years) were enrolled in the study and 
163 subjects completed the experimental protocol between July 2009 and October 2010. The 
subjects included in this study are a subset of a larger study; the data collected from all 163 
subjects were analyzed elsewhere. Samples were analyzed for a total of 50 subjects (33 females 
and 17 males; 19-53 years); subjects were randomized by each BGI strata to a total of 10 
subjects per stratum. Eligibility criteria included: adult male or females; age range: 18 to 75 
years; good general health; ≥8 teeth in a functional dentition with a minimum of 3 adjacent teeth 
with interproximal papilla in each posterior sextant; that may be classified into one of the 
following five categories: BGI-H (all PD≤3mm, BOP<10%), BGI-G (all PD≤3mm, BOP≥10%), 
BGI-P1 (≥1 site with PD>3mm, BOP≤10%), BGI-P2 (≥1 site with PD>3mm, 50% ≥BOP>10%), 
BGI-P3 (1≥ site with PD>3mm, BOP>50%). Exclusion criteria included: (1) individuals who 
have a chronic disease with oral manifestations or active infectious diseases such as hepatitis, 
HIV or tuberculosis; (2) individuals who exhibit gross oral pathology; (3) treatment with 
antibiotics for any medical or dental condition within one month prior to the study; (4) chronic 
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treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., 
phenytoin, calcium antagonists, cyclosporin, anticoagulants, non-steroidal anti-inflammatory 
drugs, high dose aspirin such as >100mg per day) within one month prior to the study; (5) 
ongoing medications initiated less than three months prior to enrollment (i.e., medications for 
chronic medical conditions must be initiated at least three months prior to enrollment); (6) 
participants with clinically significant organ disease including impaired renal function, and/or 
any bleeding disorder; (7) severe unrestored caries, or any condition that is likely to require 
antibiotic treatment during the study, including the need for prophylactic antibiotic; (8) 
individuals who use any tobacco products or who have used tobacco products within the 
previous six months of the study; (9) individuals who are pregnant, or expect to become 
pregnant, within the next three months and individuals nursing. Participants were excluded from 
the study or analysis if any of the following conditions occurred: (1) changes in the participant's 
medical status or medications; (2) use of any antibacterial rinses; (3) use of non-study 
dentifrices, toothbrushes or dental floss during the no-hygiene and resolution phases of the study; 
(4) use of irrigating devices or other interdental aids; (5) participant’s inability or noncompliance 
to wear their stents or shields over the selected no-hygiene sextants during daily brushing 
procedures; (6) use of oral antibiotics and non-steroidal anti-inflammatory drugs during the trial. 
Acute use of oral acetaminophen was permitted. Participants requiring treatment for an acute 
medical or dental condition during the study were withdrawn from the trial. 
 
Patient protocol and procedures 
At the screening visit (visit 1) informed consent was obtained, medical history, height, 
weight and vital signs were collected, a full-mouth clinical examination was performed and 
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impressions were made for stent fabrication. Full mouth-examination included oral cancer 
screening, GI (Löe & Silness, 1963), PI (Silness & Löe, 1964), PD, CAL and BOP scores 
(yes/no) at each of six sites per tooth. Customized stents were fabricated for each subject to 
encourage participant compliance during daily brushing procedures. Stents resembled an acrylic 
occlusal guard but extended to cover approximately 2 mm over gingival margins. Stents formed 
a seal and rested on the gingiva, but were relieved on the tooth and tissue side except for occlusal 
surfaces to avoid disturbing plaque or gingival tissues. Within two weeks at visit 2 (Day -14) the 
exam was repeated and biological samples were collected: 3 mL of whole, unstimulated saliva 
was collected. At visit 2, standardized study products including fluoride dentifrice and a 
toothbrush were dispensed and subjects were instructed on toothbrush technique. Following a 2-
week hygiene phase, participants returned for the baseline (Day 0) visit. At this visit subjects 
were given two stents and instructions for use. From this point forward for a 3-week, no-hygiene 
phase, subjects abstained from all oral hygiene procedures in two posterior sextants via 
placement of acrylic stents. At baseline (Day 0), saliva was collected, clinical exams performed, 
vitals, adverse events recorded and medical histories updated. All participants refrained from all 
oral hygiene procedures (i.e., tooth brushing, flossing or use of interdental aids) in two sextants 
that were preselected as the upper right (teeth #1-6) and lower right (teeth #27-32); if there were 
fewer than four teeth in a sextant then the contralateral sextant was selected. Participants were 
directed to continue plaque removal procedures to the remaining four sextants using the fluoride 
dentifrice provided at visit 2 (Day -14). Participants were instructed to discontinue flossing 
altogether to prevent inadvertently flossing stent teeth. Subjects were seen on Day 7, 14 and 21 
for saliva collection during the induction phase and clinical exams were performed at each visit 
to assure patient safety and compliance. At Day 21, subjects were provided oral hygiene 
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instruction, both verbally and in writing, and advised to brush their entire dentition twice a day 
and continue to abstain from flossing during the 4-week resolution phase (Days 21-49). Subjects 
returned on Day 35 for repeated clinical exam and biological sampling of saliva. Subjects 
returned on Day 49 (four weeks after reinstating oral hygiene) for repeated clinical exam and 
biological sampling of saliva. Upon exit of the study, oral prophylaxis or scaling root planing 
was performed on all subjects to regain periodontal health. Day 21 represents the peak of 
gingival inflammation induction while Day 49 represents the peak of gingival inflammation 
resolution.  
Saliva samples were collected from subjects on Day -14, 0, 7, 14, 21, 35 and 49. At each 
of these time points, approximately 3 mL of unstimulated saliva was collected into a 15 mL 
conical tube. Subjects refrained from eating, drinking, chewing gum, breath mints, etc., or 
performing oral hygiene procedures for at least one hour prior to saliva collection. This request 
was made after consenting for the first sample collection. Saliva was collected using a 15 mL 
polypropylene tube. The subject spit into the collection vessel but was instructed to avoid 
coughing up mucus. During saliva collection, the collection vessel was kept at room temperature, 
centrifuged and aliquoted into three samples of 0.5 mL in each tube. Remaining saliva was 
aliquoted into a fourth tube and samples were stored at -80C.  
 
Examiner training and calibration 
Clinical examiners were calibrated before commencement of the study for training of 
study procedures and for documentation of acceptable intra- and inter-examiner measurement 
reliability. This examiner calibration and training is under a separate IRB-approved protocol that 
is performed within the General and Oral Health Center at UNC School of Dentistry. Examiners 
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were standardized on measurements of the PI, GI, PD, CAL and BOP. The three participating 
examiners were found to have an intra-class k coefficient of agreement between 0.94-0.98 for PD 
and between 0.77-0.97 for CAL measurements, as compared with the gold standard examiner. 
Clinical parameters were measured using a manual UNC-15 periodontal probe. For experimental 
SIBO measures, these parameters were measured at six sites per tooth for teeth within the two 
experimental SIBO sextants and for teeth in the other four sextants for control purposes. 
Examiners were masked to the subject’s BGI category. 
 
Analysis of the salivary metabolome  
Metabolomic analyses were conducted at Metabolon, Inc. (Durham, NC). Samples were 
subjected to both non-targeted and targeted analysis via LC/MS and GC/MS as described by 
Evans et al. (2012) (Evans, Mitchell, Dai, & DeHaven, 2012). Saliva samples were analyzed in 
duplicate from timepoints -14, 0, 7, 14, 21, 35 and 49 days for each subject. Results were 
reported as raw concentrations of metabolites for five groups (BGI-H, BGI-G, BGI-P1, BGI-P2, 
and BGI-P3) at seven time points (Day -14, 0, 7, 14, 21, 35 and 49) which provided data at 
baseline, induction and resolution. All laboratory analyses were performed masked from sample, 
visit or subject information. Extended details of methods are included in Appendix 3.1.1. 
 
Statistical analysis 
Statistical analyses was performed using SPSS 22.0 software (SPSS, Inc., Chicago, IL). 
For demographic variables, a chi-squared test (2) was used to determine statistical significance 
between categorical variables and general linear models were used to determine statistical 
significance between means. For clinical indices, general linear models were used to compare 
17 
 
days 7–21 with baseline and days 35 and 49 with peak of induction (day 21). Statistical 
significance is reported for p<0.05, p<0.001, and p<0.0001. Paired t-tests were used to compare 
mean metabolites at peak of induction with baseline and peak of resolution with peak of 
induction. FDR was applied to correct for multiple comparisons and was reported as q-values. 
Since very few changes were statistically significant by FDR, unadjusted p-values were reported 
to demonstrate trending changes. Covariance matrices were applied to describe correlations 
between changes in metabolites and changes in clinical indices at peak of induction (Day 21). r 
values were reported with corresponding p-values and q-values determined by paired t-tests and 
FDR respectively.  
 
Section 3.3: Results 
Study implementation 
357 subjects were screened to reach the target enrollment. Subjects were recruited in two 
phases to provide interim data on disease states: (1) BGI-P1, BGI-P2, BGI-P3; (2) BGI-H, BGI-
G. Participants were recruited by advertisement including email, flyers, internet postings and 
newspaper ads from the patient, student, and staff population at UNC Chapel Hill and the general 
population. 182 subjects did not meet the inclusion criteria and were excluded from the study. 
175 subjects met the inclusion criteria, were enrolled in the study, and were classified by BGI 
category: BGI-H (36 subjects), BGI-G (34 subjects), BGI-P1 (33 subjects), BGI-P2 (37 subjects) 
and BGI-P3 (35 subjects). In the BGI-H category, two subjects dropped out due to medical 
conditions; in the BGI-G category, one subject dropped out due to time constraints; in the BGI-
P1 category, one subject dropped out since she was not comfortable abstaining from oral 
hygiene; in the BGI-2 category, five subjects dropped out due to time constraints; in the BGI-P3 
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category, three subjects dropped out due to time constraints. 163 subjects completed the study in 
the following BGI categories: BGI-H (34 subjects), BGI-G (33 subjects), BGI-P1 (32 subjects), 
BGI-P2 (32 subjects) and BGI-P3 (32 subjects). Patient flow is illustrated in Figure 1. Samples 
were analyzed for a total of 50 subjects; subjects were randomized by each BGI strata to a total 
of 10 subjects per stratum. The mean age of the 50 subjects was 31.0 (standard deviation, 9.2), 
comprising 26 African Americans, 20 Caucasians, four other, 33 females and 17 males. 
Demographic information is provided in Table 1.1. Among the demographic variables presented 
in Table 1.1, age, former smoking and BMI are potential biases. Baseline clinical indices by BGI 
category are provided in Table 1.2, 
 
Changes in clinical signs during induction and resolution of experimental SIBO 
The SIBO model has practical advantages as compared with the traditional experimental 
gingivitis model described by Löe et al. (1965) in which total abstinence from oral hygiene 
procedures was required. Specifically, subjects prefer to be able to limit the extent of gingival 
inflammation to selected posterior regions of the mouth and to be able to use dentifrice and 
normal brushing on the remainder of the dentition and tongue to improve oral freshness (Löe et 
al., 1965). During the 3-week induction phase, SIBO was associated with an overall increase in 
clinical signs of inflammation and plaque scores that was limited to the stent area (Table 2.1). 
Clinical indices during induction and resolution of experimental SIBO by BGI category are 
shown in Table 2.2. Using general linear models, the increases seen in PI and GI are statistically 
significant by one week and increased in magnitude through Day 21 (p<0.001) in each of the 
BGI categories with the exception of BGI-P3. After reinstating oral hygiene at Day 21, there is a 
statistically significant decrease in mean PI and GI in each of the BGI categories at Days 35 and 
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49 as compared with Day 21 and a return to baseline values (p < 0.05). A similar trend was seen 
for BOP which achieved statistical significance at Day 21 in each of the BGI categories with the 
exception of BGI-P3 (p < 0.05). PI, GI, BOP, PD and CAL trends are depicted in Figures 2.1-
2.5. Slight changes in PD and CAL did not reach statistical significance. Thus, there was 
induction of experimental SIBO under the stent that was fully and readily reversed by reinstating 
oral hygiene. None of the subjects required scaling root planing at Day 49.  
 
Changes in metabolome during induction and resolution of experimental SIBO 
281 metabolites, that represent breakdown products of various super-pathways 
(carbohydrate, lipid, amino acid, xenobiotics, nucleotide, cofactors and vitamins) and sub-
pathways, were quantified at each time point. At baseline, there were no significant differences 
in metabolite levels between BGI categories (FDR, q < 0.05). When mean metabolite levels were 
analyzed, without stratifying by BGI category, eight metabolites demonstrated significant 
changes between baseline and peak of induction (Day 21) using FDR-adjusted p-values (q-
values) (Table 3.1). Seven of these eight metabolites are in the amino acid super-pathway. No 
metabolites demonstrated significant changes between peak of induction (Day 21) and peak of 
resolution (Day 49) when applying FDR (data not reported).  
When mean metabolite levels were stratified by BGI category, no metabolites 
demonstrated significant changes between baseline and peak of induction (Day 21) or peak of 
induction (Day 21) and peak of resolution (Day 49) when applying FDR. Appendix 3.2 includes 
metabolite levels stratified by BGI category that demonstrated trending changes (unadjusted p-
values < 0.05).  Table 3.2 demonstrates top five trending changes in metabolite levels between 
baseline and peak of induction while Table 3.3 demonstrates trending changes in metabolite 
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levels between peak of induction and peak of resolution. A summary of changes of metabolites 
from biochemical pathways altered by experimental SIBO is depicted in Table 3.4. 
When generalized linear models and FDR were applied adjusting for age, BMI and 
former smoking, no changes in metabolites remained statistically significant (q < 0.05). It is 
possible that sample size was insufficient to capture significant changes when such rigorous 
statistical analyses were applied. 
Mean levels of threonine, N-acetylserine, and serine from the glycine, serine and 
threonine metabolism sub-pathway decreased from baseline to peak of induction (Day 21) (q < 
0.05). The glycine, serine and threonine metabolism sub-pathway is illustrated in Figure 4b.  
From this pathway, glycine demonstrated a trending decrease from baseline to peak of induction 
and increase from peak of induction to peak of resolution in the BGI-H category (unadjusted p < 
0.05) (Appendix 3.2). Additionally, homoserine, N-acetylglycine and O-acetylhomoserine, 
demonstrated trending changes in various BGI categories. There was a very strong correlation at 
peak of induction between mean levels of threonine and serine (r = 0.874) but weak correlations 
at peak of induction between mean levels of threonine and N-acetylserine (r = 0.247) and 
between N-acetylserine and serine (r = 0.071). 
Mean levels of histidine, from the histidine metabolism sub-pathway, were decreased 
from baseline to peak of induction (q = 0.03). The histidine metabolism sub-pathway is 
illustrated in Figure 4c. Histidine metabolites include trans-urocanate and cis-urocanate. Trans-
urocanate demonstrated a trending decrease from peak of induction (Day 21) to peak of 
resolution (Day 49) without stratifying by BGI category (unadjusted p < 0.05) while cis-
urocanate demonstrated a trending decrease from peak of induction (Day 21) to peak of 
resolution (Day 49) in the BGI-P1 category (unadjusted p < 0.05). Mean levels of 5-oxoproline, 
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from the glutathione metabolism sub-pathway, decreased from baseline to peak of induction (q = 
0.02). The glutathione metabolism pathway is illustrated in Figure 4d. Mean levels of glutamate 
were decreased from baseline to peak of induction (q = 0.03) (Figure 4a). Glutamate is included 
in several pathways including the histidine metabolism sub-pathway, the glutathione metabolism 
sub-pathway, the purine metabolism sub-pathway, and the alanine, aspartate and glutamine 
metabolism sub-pathway. Glutamate demonstrated a trending decrease from peak of induction 
(Day 21) to peak of resolution (Day 49) in the BGI-G category (unadjusted p < 0.05). 
Additionally, glutamine, a metabolite that shares several pathways with glutamate, demonstrated 
a trending decrease from baseline to peak of induction without stratifying by BGI category 
(unadjusted p < 0.05). There was a moderate correlation at peak of induction between mean 
levels of metabolites glutamate and 5-oxoproline (r = 0.874) which are included in the 
glutathione metabolism sub-pathway (Figure 4d). 
Mean levels of erythronate, from the aminosugars metabolism sub-pathway, were 
decreased from baseline to peak of induction (q = 0.03). Trending decreases were seen in the 
BGI-P1 category from peak of induction to peak of resolution (unadjusted p < 0.05).  
Mean levels of tyrosine, from the phenylalanine and tyrosine metabolism sub-pathway, 
were decreased from baseline to peak of induction (q < 0.05). From the phenylalanine 
metabolism sub-pathway, several metabolites including phenyllactate, P-cresol sulfate, and 
phenylacetate demonstrated trending decreases from baseline to peak of induction in the BGI-H 
category.  
Trending increases and decreases in metabolite levels from baseline to peak of induction 
(Day 21) and from peak of induction (Day 21) to peak of resolution (Day 49) were indicated as 
blue and red p-values, respectively. Interesting findings include BCAAs isoleucine and valine 
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which showed trending, although not statistically significant, decreases at peak of induction (Day 
21) as compared to baseline in the BGI-H category (unadjusted p < 0.05). Similarly, 3-
hydrohyisobutyrate and citramalate, which are members of the valine, leucine and isoleucine 
metabolism pathway, also showed trending, although not statistically significant, decreases at 
peak of induction (Day 21) as compared to baseline in the BGI-H category (unadjusted p < 0.05).  
 
Changes in clinical indices that co-vary with changes in metabolites  
Covariance matrices were applied to describe correlations between mean changes in 
metabolites and changes in clinical indices at peak of induction (Day 21). When changes in mean 
metabolites were analyzed without stratifying by BGI category, no metabolites with q < 0.05 
were noted (Table 4.1). A weak negative correlation was noted between changes in CAL at peak 
of induction and mean changes in glycine (r = -0.34, p = 0.02) and taurine (r = -0.3, p = 0.03) 
which were statistically significant. A weak positive correlation was noted between changes in 
BOP at peak of induction and mean changes in 5-oxoproline (r = 0.25, p = 0.08) and cis-
uroconate (r = 0.27, p = 0.06) which was not statistically significant (data not reported).  
When changes in metabolite levels were stratified by BGI category, two metabolites 
demonstrated very strong positive correlations that were statistically significant with changes in 
BOP in the BGI-P1 group: 3-aminoisobutyrate (nucleotide super-family, r = 0.92, p < 0.01, q = 
0.03) and 1,3-diaminopropane (amino acid super-family, r = 0.91, p < 0.01, q = 0.03) at peak of 
induction (Appendix 3.3). 3-aminoisobutyrate demonstrated a trending decrease in BGI-P1 from 
baseline to peak of induction while 1,3-diaminopropane demonstrated a trending decrease in 
BGI-H from baseline to peak of induction (t-test, p< 0.05). 
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 In the BGI-H group, a strong positive correlation was noted between changes in BOP 
and mean changes of glutamate (r = 0.69, p = 0.03) and glutamine (r = 0.64, p = 0.04). 
Additionally, a strong positive correlation was noted between changes in BOP and threonine in 
BGI-P2 (r = 0.68, p = 0.03), between changes in PI and GI and histidine in BGI-H (r = 0.71, p = 
0.02 and r = 0.69, p = 0.03 respectively), and between changes in PI and 5-oxoproline in BGI-P1 
(r = 0.69, p = 0.03). 
 
Section 3.4: Discussion 
Proteolytic bacteria degrade nitrogenous compounds producing peptides and amino acids 
that can be further metabolized by the bacterium and serve as additional nutrient sources. When 
mean metabolite levels were analyzed by FDR, without stratifying by BGI category, eight 
metabolites (0.03%) demonstrated significant decreases between baseline and peak of induction, 
including seven metabolites from the amino acid super-pathway. At baseline, there were no 
significant differences in metabolite levels between BGI categories. As such, it is not possible to 
differentiate between disease states with cross-sectional measurements of metabolites at baseline. 
This finding is in agreement with Barnes et al. 2011 who demonstrated very few significant 
differences between disease categories (0.02% of metabolites differed significantly between 
periodontal health and periodontitis). When mean metabolites were stratified by BGI category 
and analyzed by FDR, no changes between baseline, peak of induction and peak of resolution 
were statistically significant but trending changes were noted (Tables 3.2, 3.3). It appears that the 
power of this study was insufficient to demonstrate statistically significant changes by BGI 
category by FDR. Trending changes may implicate important metabolic pathways and should not 
be ignored.  
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Threonine, N-acetylserine, and serine, from the serine and threonine metabolism sub-
pathway, decreased from baseline to peak of induction (q < 0.05). Threonine bridges the glycine, 
serine and threonine metabolism sub-pathway and the valine, leucine and isoleucine biosynthesis 
sub-pathway. Interestingly, trending decreases of isoleucine, valine, 3-hydroxyisobutyrate and 
citramalate, from the valine, leucine and isoleucine metabolism sub-pathway, were noted in the 
BGI-H category from baseline to peak of induction. Additionally, glycine, which is an 
intermediate metabolite between serine and threonine, demonstrated a trending decrease from 
baseline to peak of induction and increase from peak of induction to peak of resolution in the 
BGI-H category (unadjusted p < 0.05). The statistically significant decrease in threonine, N-
acetylserine, and serine and trending non-significant decrease in glycine, isoleucine, valine, 3-
hydrohyisobutyrate and citramalate may represent a feature of the gingival bacterial populations 
reliance on protein breakdown and amino acid catabolism for energy and specifically the serine 
and threonine metabolism and valine, leucine and isoleucine metabolism sub-pathways. The very 
strong correlation at peak of induction between mean levels of threonine and serine (r = 0.874) 
strengthens this postulation. These findings are in contrast with those of Barnes et al. (2011) who 
studied salivary metabolites in human subjects with periodontal health and periodontitis and 
demonstrated that while dipeptides were elevated, amino acids were unchanged with the 
exception of cysteine, which was elevated (Barnes et al., 2011).   
Barnes et al. (2009) conducted metabolomic analysis of GCF samples collected from 
healthy, gingivitis, and periodontitis sites in humans (Barnes et al., 2009). Levels of putrescine 
and cadaverine, which are the end-products of amino acid degradation, were upregulated by 
disease. The authors suggested that host tissues upregulate the purine degradation pathway as a 
defense mechanism against oxidant-sensitive bacterial pathogens. Interestingly, neither 
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putrescine nor cadaverine demonstrated statistically significant changes at peak of induction and 
peak of resolution in this study (data not reported). Cadaverine demonstrated a trending increase 
at peak of induction compared to baseline and a trending decrease at peak of resolution as 
compared to peak of induction when samples were not stratified by BGI category (unadjusted p 
<0.05). It is possible that reduced concentrations of these metabolites in saliva as compared with 
GCF accounts for this effect.  
Mean changes of glutamate were statistically significantly decreased from baseline to 
peak of induction. Since glutamate is an amino acid that is commonly metabolized by oral 
bacteria (Takahashi, Sato, & Yamada, 2000), the decrease observed in this study strengthens the 
postulation that gingival bacterial populations rely on amino acid catabolism for energy and 
specifically glutamate for carbon and sulfur metabolism. When samples were pooled, glutamine 
demonstrated a trending decrease from baseline to peak of induction. Glutamine is derived from 
proteolysis of host tissues, and serves as a precursor for glutamate (Nurjhan et al., 1995). 
Additionally, reduced levels of glutamate will drive the reaction of glutamine to glutamate via 
the enzyme glutaminase (glutamine and glutamate metabolism sub-pathway, Figure 4a) that 
releases additional ammonia that will serve to raise the pH of the environment. In fact, 
periodontitis is associated with a rise in pH above neutrality and increased probing depth and 
inflammation have been correlated with increased alkalization (Bickel & Cimasoni, 1995; Holt 
& Ebersole, 2005). 
Amino acids histidine and histidine metabolites trans- and cis-urocanate have been shown 
to have anti-inflammatory activities (Hasegawa et al., 2012). In addition, trans-urocanate can be 
further metabolized to glutamate and thus serve as a potential energy source for bacteria. Mean 
changes of histidine were statistically significantly decreased from baseline to peak of induction 
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while changes in trans-urocanate and cis-urocanate demonstrated trending decreases from peak 
of induction to peak of resolution. Lower levels of histidine and the urocanates at peak of 
induction and peak of resolution could have negative consequences on oral health due to their 
anti-inflammatory properties. Glutamate and histidine share several metabolic pathways 
including the histidine metabolism sub-pathway and the purine metabolism sub-pathway. 
Statistically significant decreases in mean levels of these two metabolites at peak of induction 
may suggest an important role of these two pathways in the initiation of periodontal 
inflammation. Like the glutamine and glutamate metabolism sub-pathway, the reaction from 
histidine to the urocanates increases ammonia. This pathway may also serve to raise the pH of 
the environment. 
Additionally, mean changes of 5-oxoproline were statistically significantly decreased 
from baseline to peak of induction (q = 0.02). 5-oxoproline is hydrolyzed to glutamate by 5-
oxoprolinase (Figure 4d). Additionally, glutamine, which shares multiple metabolic pathways 
with glutamate, demonstrated a trending decrease from baseline to peak of induction. The 
finding that 5-oxoproline was statistically significantly decreased from baseline to peak of 
induction and glutamine demonstrated a trending decrease from baseline to peak of induction 
further strengthens the suggestion that glutamate is an important energy source for bacterial 
populations in periodontal inflammation. By-products of the glutathione metabolism sub-
pathway are energy by-products including ADP and NADPH which serve to alter the redox 
potential of the local environment (Main et al., 2012). Additionally, conversion of glutamate to 
glutathione results in oxidation of reactive oxygen species which has been implicated in several 
other diseases such as cardiovascular disease, ischemic-reperfusion injury, diabetes, hypertension 
and inflammatory disease (Chae et al., 2013; Ren, Zhang, Cui, & Mu, 2013). Paradoxically, 
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Barnes et al. (2013) demonstrated elevated 5-oxoproline, glutamate, cysteine, γ-glutamyl-AA, 
glutathione disulfide (oxidized) and cysteine-glutathione disulfide (components of glutathione 
metabolism) in saliva when comparing diabetic and non-diabetic subjects with healthy 
periodontium, gingivitis and periodontitis (Barnes et al., 2013, March). However, this effect was 
more pronounced in diabetic subjects.  
Erythronate is an organic acid present in healthy adults and children in the aqueous 
humor of the eye, connective tissue, urine, plasma, cerebrospinal fluid and synovial fluid 
(Harding, Hassett, Rixon, Bron, & Harvey, 1999).  Erythronate is formed when N-Acetyl-D-
glucosamine is oxidized (Jahn, Baynes, & Spiteller, 1999). N-Acetyl-D-glucosamine is a 
component of hyaluronic acid which is glycosaminoglycan found in human connective tissue 
inclusive of the periodontium (Sukumar & Drizhal, 2007).  Erythronate is also derived from 
degradation of ascorbic acid, which is an anti-oxidant (Harding et al., 1999). Mean changes of 
erythronate were statistically significantly decreased from baseline to peak of induction (q < 
0.05).  To our knowledge, erythronate has not been investigated in gingivitis and periodontitis. 
Barnes et al. (2009) reported a statistically significant decrease in ascorbic acid found in the GCF 
of diseased sites. Since oxidative stress has been implicated in the pathogenesis of periodontitis 
(Galli, Passeri, & Macaluso, 2011), decreased levels of anti-oxidants such as ascorbic acid would 
be expected. It is possible that decreased levels of erythronate detected in this study at peak of 
induction reflects an enhanced oxidative state.  
BCAAs isoleucine and valine showed trending, although not statistically significant, 
decreases at peak of induction as compared to baseline in the BGI-H category (unadjusted p < 
0.05). BCAAs are among the most common amino acids metabolized by oral bacteria. Other 
mediators of the valine, leucine and isoleucine metabolism pathway, including 3-
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hydrohyisobutyrate and citramalate, showed trending changes in the BGI-H category (unadjusted 
p < 0.05). The lack of similar changes in the other four disease states could reflect a pre-existing 
hyper-inflammatory state. 
Tyrosine is an essential amino acid that is involved in several functions including 
neurotransmitter and hormone synthesis and is rapidly metabolized (Rasmussen, Ishizuka, 
Quigley, & Yen, 1983). It is involved in a number of pathways including phenylalanine and 
tyrosine metabolism sub-pathways. Mean changes of tyrosine were statistically significantly 
decreased from baseline to peak of induction (q < 0.05) which reinforces the suggestion that 
gingival bacterial populations rely on amino acid catabolism for energy. Trending decreases 
were seen among several metabolites in the phenyalanine metabolism sub-pathway including P-
cresol sulfate and phenylacetate. These results are in contrast with Barnes et al. (2011) who 
demonstrated no significant difference in tyrosine and a trending increase in P-cresol sulfate in 
subjects with periodontitis as compared to healthy subjects (Barnes et al., 2011). One must be 
cautious in comparing these results since Barnes et al.(2011) reports cross-sectional data while 
this study was longitudinal.   
Our data indicate that some changes in clinical indices co-vary with changes in 
metabolites in BGI categories. Changes in BOP within the BGI-P1 category demonstrate the 
strongest correlation with two metabolites, 3-aminoisobutyrate and 1,3-diaminopropane, from 
the nucleotide and amino acid super-family, respectively. To our knowledge, aminoisobutyrate 
and 1,3-diaminopropane have not been investigated in gingivitis and periodontitis.  
3-aminoisobutyrate is the end-product of pyramidine metabolism and originates from 
catabolism of thymine and valine. Studies have demonstrated persistently elevated levels of 3-
aminoisobutyrate in patients with deficiency of R (-) -b- aminoisobutyrate-pyruvate 
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aminotransferase and transiently elevated levels of 3-aminoisobutyrate in lead poisoning, 
starvation, total body irradiation, malignancies, neurological disorders and developmental delay 
(van Gennip et al., 1987). Elevated levels have been suggested to contribute to neurological and 
developmental problems since it is a structural analog for gamma-aminobutyric acid and glycine 
which are two major inhibitory neurotransmittors in the central nervous system (van Kuilenburg 
et al., 2004). 1,3-diaminopropane is a member of both the arginine and proline and beta-alanine 
metabolic pathways. Abnormal levels found in breast cancer and leukemia (Byun et al., 2008; 
Lee et al., 1998). 
Strong positive correlations between changes in BOP and glutamate and glutamine at 
peak of induction in the BGI-H category contradict previously reported data in this manuscript. 
Recall that when samples were not stratified by BGI category, mean levels of glutamate were 
statistically significantly decreased from baseline to peak of induction and mean levels of 
glutamine demonstrated a trending decrease from baseline to peak of induction. Since BGI-G, 
P1, P2 and P3 categories have an increased clinical inflammatory status, slight increases in 
glutamate and glutamine in the BGI-H group may have been masked when all subjects were 
analyzed together. It would be interesting to investigate changes in clinical indices and changes 
in glutamate and glutamine using the SIBO model with larger sample sizes to see if the 
correlation is stronger. Similarly, strong positive correlations between various clinical indices 
and threonine, histidine and 5-oxoproline in various BGI categories contradict previously 
reported data in this manuscript which may be related to the relatively small sample size.   
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Section 3.5: Conclusion 
Among the 281 biochemicals identified in the saliva from the subjects in this study, only 
eight metabolites demonstrated a statistically significant change (applying FDR, q < 0.05) from 
baseline to peak of induction when samples were not stratified by BGI category. When samples 
were stratified by BGI category, no statistically significant changes were noted (applying FDR, q 
< 0.05). Trending changes were noted in each BGI category (unadjusted p-values).  Our data 
indicate that two metabolites demonstrate very strong correlation with changes in BOP (applying 
FDR, q < 0.05) in the BGI-P1 category. This finding warrants further investigation. The 
relatively low sample number per group in conjunction with the normal high level of variability 
in human subjects likely contributed to the low number of observed differences achieving 
statistical significance. Trending changes observed in this study may provide an avenue for 
future investigation with larger sample sizes.  
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TABLE 1.1: DEMOGRAPHICS BY BGI CATEGORY (N = 50) 
Characteristic (All) BGI-H BGI-G BGI-P1 BGI-P2 BGI-P3 p-value* 
Sex      0.21 
 Female 7 (21.2%) 7 (21.2%) 9 (27.3%) 6 (18.2%) 4 (12.1%)  
 Male 3 (17.7%) 3 (17.7%) 1 (5.9%) 4 (23.5%) 6 (35.3%)  
Race      0.87 
 African American 6 (23.1%) 6 (23.1%) 5 (19.2%) 6 (23.1%) 3 (11.5%)  
 Caucasian 3 (15.0%) 3 (15.0%) 4 (20.0%) 4 (20.0%) 6 (30.0%)  
 Other 1 (25.0%) 1 (25.0%) 1 (25.0%) 0 (0.0%) 1 (25.0%)  
Diabetes      0.40 
 Yes 0 (0.0%) 1 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%)  
 No 10 (20.4%) 9 (18.4%) 10 (20.4%) 10 (20.4%) 10 (20.4%)  
Former Smoker      0.054 
 Yes 0 (0.0%) 2 (28.5%) 4 (57.1%) 1 (14.3%) 0 (0.0%)  
 No 10 (23.3%) 8 (18.6%) 6 (14.0%) 9 (20.8%) 10 (23.3%)  
Mean Age (StdDev) 26.4 (4.9) 30.9 (8.3) 38.0 (11.9) 32.4 (7.0) 27.5 (9.3) 0.03 
Mean BMI (StdDev) 23.8 (4.5) 31.4 (7.2) 28.5 (7.0) 29.2 (5.2) 25.9 (6.8) 0.08 
*Chi-squared test (2) used to determine statistical significance between categorical variables. 
General linear models used to determine statistical significance between means. 
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TABLE 1.2: BASELINE CLINICAL INDICES BY BGI CATEGORY (N = 50) 
Clinical index BGI-H BGI-G BGI-P1 BGI-P2 BGI-P3 
PI 0.57 (0.11) 0.79 (0.09) 0.58 (0.13) 1.09 (0.08) 1.27 (0.14) 
GI 0.71 (0.11) 1.00 (0.07) 0.77 (0.09) 1.21 (0.04) 1.38 (0.09) 
BOP 7.53 (1.81) 33.5 (6.12) 8.78 (1.40) 37.3 (4.61) 64.6 (2.97) 
PD 1.80 (0.05) 2.09 (0.07) 1.95 (0.09) 2.19 (0.06) 2.23 (0.07) 
CAL 0.90 (0.05) 1.00 (0.05) 0.99 (0.06) 0.94 (0.04) 1.07 (0.09) 
 Mean clinical values (standard error) for stent side at screening (Day -7).  
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TABLE 2.1 – MEAN CLINICAL CHANGES DURING INDUCTION AND RESOLUTION OF 
EXPERIMENTAL SIBO (N = 50) 
 
 
Baseline Stent in place         
 
Resolution 
  
Day 7 Day 14 Day 21 Day 35 Day 49 
Mean PI 0.75 (0.06) 1.39 (0.06)
†
 1.49 (0.06)
†
 1.54 (0.06)
†
 0.76 (0.07)
†
 0.76 (0.07)
†
 
Mean GI 0.86 (0.04) 1.05 (0.04)** 1.16 (0.04)
†
 1.19 (0.04)
†
 0.84 (0.04)
†
 0.88 (0.04)
†
 
BOP 28.6 (2.48) 37.3 (2.51)* 46.5 (2.48)
†
 48.0 (2.48)
†
 26.9 (2.62)
†
 30.6 (2.64)
†
 
Mean PD 2.14 (0.04) 2.15 (0.05) 2.18 (0.04) 2.20 (0.04) 2.07 (0.05)* 2.18 (0.05) 
Mean AL 1.09 (0.04) 1.05 (0.04) 1.04 (0.04) 1.08 (0.04) 1.00 (0.04) 1.07 (0.04) 
Mean clinical values (standard error) for stent side. General linear model used to compare Days 
7–21 with baseline and Days 35 and 49 with Day 21; p-value: *p<0.05, **p<0.001, †p<0.0001. 
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TABLE 2.2 – MEAN CLINICAL CHANGES DURING INDUCTION AND RESOLUTION OF 
EXPERIMENTAL SIBO BY BGI CATEGORY (N = 50 TOTAL; N = 10 PER BGI 
CATEGORY) 
 
  
Baseline Stent in place         
 
Resolution 
 
BGI 
 
Day 7 Day 14 Day 21 Day 35 Day 49 
 H 0.37 (0.14) 1.19 (0.14)
†
 1.35 (0.14)
†
 1.48 (0.14)
†
 0.71 (0.16)** 0.56 (0.16)
†
 
 G 0.62 (0.11) 1.30 (0.11)
†
 1.28 (0.11)
†
 1.39 (0.11)
†
 0.62 (0.12)
†
 0.62 (0.13)
†
 
Mean PI P1 0.76 (0.11) 1.56 (0.11)
†
 1.76 (0.11)
†
 1.50 (0.11)
†
 0.81 (0.11)
†
 0.93 (0.11)**  
 
P2 0.77 (0.11) 1.47 (0.11)
†
 1.46 (0.11)
†
 1.59 (0.11)
†
 0.68 (0.11)
†
 0.73 (0.11)
†
 
 
P3 1.21 (0.19) 1.46 (0.19) 1.62 (0.19) 1.73 (0.19) 0.96 (0.19)* 0.84 (0.19)* 
 H 0.50 (0.10) 0.91 (0.10)* 1.01 (0.10)** 1.01 (0.10)** 0.87 (0.12) 0.56 (0.12)* 
 G 0.74 (0.07) 0.99 (0.07)* 1.15 (0.07)** 1.12 (0.07)** 0.83 (0.08)* 0.89 (0.08)* 
Mean GI P1 0.86 (0.06) 1.06 (0.06)* 1.13 (0.06)* 1.12 (0.06)* 0.75 (0.06)
†
 0.97 (0.06) 
 
P2 1.00 (0.08) 1.18 (0.08) 1.24 (0.08)* 1.31 (0.08)* 0.76 (0.08)
†
 0.89 (0.08)** 
 
P3 1.19 (0.09) 1.13 (0.09) 1.27 (0.09) 1.38 (0.09) 1.02 (0.09)* 1.02 (0.09)* 
 H 14.1 (4.44) 28.9 (4.44)* 32.5 (4.44)* 35.1 (4.44)* 20.0 (5.30)* 24.3 (5.30) 
 G 23.0 (4.45) 31.7 (4.45) 41.8 (4.45)* 47.8 (4.45)** 26.9 (4.98)* 34.8 (5.31) 
BOP P1 21.5 (4.84) 31.8 (4.84) 49.0 (4.84)** 47.2 (4.84)** 26.3 (4.84)* 29.6 (4.84)* 
 
P2 34.5 (4.80) 48.7 (5.06)* 51.3 (4.80)* 53.7 (4.80)* 20.0 (4.80)
†
 30.1 (4.80)* 
 
P3 49.7 (6.48) 46.6 (6.48) 57.6 (6.48) 56.1 (6.48) 39.4 (6.48) 33.7 (6.48)* 
 H 1.94 (0.11) 2.00 (0.11) 2.05 (0.11) 2.01 (0.11) 1.82 (0.13) 1.98 (0.13) 
 G 2.22 (0.12) 2.19 (0.12) 2.27 (0.12) 2.22 (0.12) 2.10 (0.14) 2.09 (0.15) 
Mean PD P1 2.05 (0.09) 2.11 (0.09) 2.17 (0.09) 2.28 (0.09) 2.24 (0.09) 2.16 (0.09) 
 
P2 2.16 (0.07) 2.18 (0.07) 2.15 (0.07) 2.19 (0.07) 1.96 (0.07)* 2.14 (0.07) 
 
P3 2.33 (0.09) 2.28 (0.09) 2.26 (0.09) 2.29 (0.09) 2.16 (0.09) 2.46 (0.09) 
 H 1.06 (0.09) 1.05 (0.09) 1.00 (0.09) 1.04 (0.09) 0.84 (0.11) 0.99 (0.11) 
 G 1.09 (0.08) 0.99 (0.08) 1.08 (0.08) 1.04 (0.08) 0.94 (0.09) 0.97 (0.09) 
Mean AL P1 1.16 (0.08) 1.05 (0.08) 0.95 (0.08) 1.14 (0.08) 1.03 (0.08) 0.93 (0.08) 
 
P2 1.08 (0.06) 1.00 (0.06) 1.11 (0.06) 0.98 (0.06) 1.05 (0.06) 1.06 (0.06) 
 
P3 1.06 (0.08) 1.17 (0.08) 1.07 (0.08) 1.21 (0.08) 1.07 (0.08) 1.34 (0.08) 
Mean clinical value (standard error) for stent side. General linear model used to compare Days 
7–21 with baseline and Days 35 and 49 with Day 21; p-value: *p<0.05, **p<0.001, †p<0.0001. 
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TABLE 3.1 – MEAN METABOLITE LEVELS DURING INDUCTION AND RESOLUTION 
OF EXPERIMENTAL SIBO (N = 50) 
 
Metabolite Super-pathway Sub-pathway Baseline Day 21 Day 49 q-value 
Threonine Amino acid 
Glycine, serine and 
threonine metabolism 
0.40 0.29 0.32 <0.01 
N-acetylserine Amino acid 
Glycine, serine and 
threonine metabolism 
0.31 0.23 0.25 0.02 
Serine Amino acid 
Glycine, serine and 
threonine metabolism 
0.40 0.30 0.31 0.02 
5-oxoproline Amino acid Glutathione metabolism 0.36 0.27 0.32 0.02 
Histidine Amino acid Histidine metabolism 0.35 0.29 0.32 0.03 
Glutamate Amino acid Glutamate metabolism 0.36 0.30 0.31 0.03 
Erythronate Carbohydrate 
Aminosugars 
metabolism 
0.34 0.29 0.32 <0.05 
Tyrosine Amino acid 
Phenylalanine & 
tyrosine metabolism 
0.34 0.29 0.30 <0.05 
Log of mean metabolites reported as raw concentrations. FDR-adjusted p-values (q-values) were 
used to compare peak of induction (Day 21) with baseline, only metabolites with q < 0.05 were 
reported. FDR was used to compare peak of resolution (Day 49) with peak of induction (Day 
21); no metabolites with q < 0.05 were noted (data not reported). 
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TABLE 3.2 – TOP FIVE MEAN METABOLITE LEVELS DURING INDUCTION OF 
EXPERIMENTAL SIBO BY BGI CATEGORY (N = 50; N = 10 PER BGI CATEGORY)  
 
BGI Metabolite 
Super-
pathway 
Baseline Day 21 Day 49 p-value* q-value
†
 
H Panose Carbohydrate 0.38 0.25 0.28 <0.01 0.13 
Glycyltyrosine Peptide 0.45 0.27 0.34 <0.01 0.13 
Isobar: dihydrocaffeate, 
3,4-dihydroxycinnamate 
Xenobiotics 0.40 0.30 0.46 <0.01 0.13 
Pantothenate 
Cofactors and 
vitamins 
0.38 0.27 0.32 <0.01 0.13 
5,6-dihydrothymine Nucleotide 0.39 0.27 0.35 <0.01 0.13 
G Homoserine Amino acid 0.33 0.26 0.25 0.02 0.92 
Hippurate Xenobiotics 0.30 0.39 0.29 0.03 0.92 
Glycylleucine Peptide 0.27 0.34 0.30 0.03 0.92 
Phosphoethanolamine Lipid 0.31 0.37 0.28 0.13 0.92 
Adenine Nucleotide 0.22 0.31 0.38 0.19 0.92 
P1 2-hydroxy-3-
methylvalerate 
Amino acid 0.29 0.22 0.36 0.02 0.92 
Creatine Amino acid 0.15 0.35 0.26 0.02 0.92 
5-oxoproline Amino acid 0.39 0.29 0.28 0.03 0.92 
Thymine Nucleotide 0.30 0.19 0.20 0.04 0.92 
3-aminoisobutyrate Nucleotide 0.13 0.22 0.17 0.04 0.92 
P2 
Alpha-tocopherol 
Cofactors and 
vitamins 
0.41 0.26 0.44 <0.01 0.23 
Carnitine Lipid 0.35 0.16 0.23 <0.00 0.23 
2-aminophenol Amino acid 0.28 0.18 0.22 0.01 0.32 
Glycylproline Peptide 0.33 0.22 0.29 0.01 0.32 
Guanine Nucleotide 0.35 0.27 0.28 0.01 0.32 
P3 Glucose-6-phosphate  Carbohydrate 0.46 0.32 0.33 0.02 0.76 
Arginylleucine Peptide 0.39 0.31 0.29 0.04 0.76 
3-hydroxyisobutyrate Amino acid 0.36 0.28 0.33 0.04 0.76 
Glycerate Carbohydrate 0.27 0.18 0.26 0.04 0.76 
Acetylcarnitine Lipid 0.32 0.27 0.29 0.04 0.76 
Log of mean metabolites reported as raw concentrations. * unadjusted p-values used to compare 
peak of induction (Day 21) with baseline. †FDR-adjusted p-values; no metabolites with q < 0.05 
were noted. Red values indicated decreased metabolite levels from baseline to peak of induction 
(Day 21). Blue values indicated increased metabolite levels from baseline to peak of induction 
(Day 21). 
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TABLE 3.3 – TOP FIVE MEAN METABOLITE LEVELS DURING RESOLUTION OF 
EXPERIMENTAL SIBO BY BGI CATEGORY (N = 50; N = 10 PER BGI CATEGORY) 
  
BGI Metabolite 
Super-
pathway 
Baseline Day 21 Day 49 p-value* q-value
†
 
H serylleucine Peptide 0.29 0.18 0.30 <0.01 0.62 
Isobar: dihydrocaffeate, 
3,4-dihydroxycinnamate 
Xenobiotics 0.40 0.30 0.46 0.01 0.81 
citramalate Amino acid 0.35 0.24 0.31 0.01 0.81 
isoleucine Amino acid 0.38 0.28 0.36 0.02 0.81 
beta-alanine Amino acid 0.23 0.09 0.21 0.02 0.81 
G phosphoethanolamine Lipid 0.31 0.37 0.28 0.00 0.08 
adenine Nucleotide 0.22 0.31 0.38 0.01 0.97 
linolenate [alpha or 
gamma; (18:3n3 or 6)] 
Lipid 0.24 0.19 0.11 0.02 0.97 
hippurate Xenobiotics 0.30 0.39 0.29 0.03 0.97 
2-aminophenol Amino acid 0.32 0.31 0.23 0.03 0.97 
P1 hypotaurine Amino acid 0.21 0.24 0.15 0.01 0.54 
daidzein Xenobiotics 0.25 0.38 0.23 0.01 0.54 
choline phosphate Lipid 0.32 0.34 0.22 0.01 0.54 
alanylalanine Peptide 0.30 0.29 0.14 0.01 0.54 
erythritol Xenobiotics 0.25 0.33 0.23 0.02 0.54 
P2 
alpha-tocopherol 
Cofactors and 
vitamins 
0.41 0.26 0.44 0.01 0.76 
hypoxanthine Nucleotide 0.44 0.34 0.51 0.01 0.76 
lysine Amino acid 0.47 0.37 0.52 0.01 0.76 
uracil Nucleotide 0.35 0.35 0.45 0.01 0.76 
pipecolate Amino acid 0.17 0.19 0.28 0.03 0.76 
P3 pinitol Lipid 0.19 0.13 0.24 0.01 0.56 
5-oxoproline Amino acid 0.43 0.28 0.36 0.01 0.56 
sorbitol Carbohydrate 0.35 0.24 0.40 0.01 0.56 
2-
methylbutyroylcarnitine 
Amino acid 0.34 0.19 0.32 0.01 0.56 
trans-4-hydroxyproline Amino acid 0.39 0.34 0.40 0.01 0.56 
Log of mean metabolites reported as raw concentrations. * unadjusted p-values used to compare 
peak of induction (Day 21) with peak of resolution. †FDR-adjusted p-values; no metabolites with 
q < 0.05 were noted. Red values indicated decreased metabolite levels from peak of induction 
(Day 21) to peak of resolution (Day 49). Blue values indicated increased metabolite levels from 
peak of induction (Day 21) to peak of resolution (Day 49).  
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TABLE 3.4 – SUMMARY OF CHANGES OF METABOLITES FROM BIOCHEMICAL 
PATHWAYS ALTERED BY EXPERIMENTAL SIBO 
 
Biochemical pathway Change from baseline to peak of induction 
Glycine, serine and threonine metabolism Down 
Valine, leucine and isoleucine biosynthesis Down 
Glutamate metabolism Down 
Histidine metabolism Down 
Purine metabolism Down 
Glutathione metabolism Down 
Phenylalanine & tyrosine metabolism Down 
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TABLE 4.1. MEAN CHANGES IN METABOLITES THAT CO-VARY WITH CHANGES IN 
CLINICAL INDICES AT PEAK OF INDUCTION (N = 50) 
 
Clinical 
index 
Metabolite 
Super-
pathway 
Correlation 
Coefficient 
p-value 
PI 1,2-propanediol Lipid 0.39 0.01 
1,3-diaminopropane Amino acid 0.35 0.01 
1,5-anhydroglucitol  Carbohydrate 0.35 0.01 
1,6-anhydroglucose Carbohydrate 0.34 0.02 
1-kestose Xenobiotics -0.33 0.02 
1-
palmitoylplasmenylethanolamine 
Lipid 0.32 0.02 
12-HETE Lipid 0.32 0.02 
13-methylmyristic acid Lipid 0.31 0.03 
2,3-dihydroxyisovalerate 
Cofactors and 
vitamins 
0.31 0.03 
2-aminoadipate Amino acid 0.30 0.03 
2-aminobutyrate Amino acid 0.30 0.03 
2-aminophenol Amino acid 0.30 0.04 
2-ethylhexyl 4-methoxycinnamate Xenobiotics 0.29 0.04 
2-hydroxy-3-methylvalerate Amino acid 0.29 0.04 
2-hydroxybutyrate  Amino acid -0.29 0.04 
2-hydroxyglutarate Lipid 0.29 0.04 
GI 4-hydroxy-3-methoxybenzyl 
alcohol 
Xenobiotics 0.44 <0.01 
2-aminophenol Amino acid 0.41 <0.01 
Cortisol Lipid 0.32 0.02 
BOP 1,2-propanediol Lipid 0.48 <0.01 
3-aminoisobutyrate Nucleotide 0.46 <0.01 
1,3-diaminopropane Amino acid 0.43 <0.01 
2-methylbutyroylcarnitine Amino acid 0.41 <0.01 
1-
palmitoylplasmenylethanolamine 
Lipid 0.34 0.01 
13-methylmyristic acid Lipid 0.34 0.01 
Adenosine 2'-monophosphate Nucleotide -0.34 0.02 
12-HETE Lipid 0.33 0.02 
4-acetamidophenol Xenobiotics 0.33 0.02 
3-(2-pyrrolidinyl)pyridine Xenobiotics 0.32 0.02 
1,5-anhydroglucitol  Carbohydrate 0.32 0.02 
2-hydroxyglutarate Lipid 0.31 0.03 
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2-hydroxy-3-methylvalerate Amino acid 0.31 0.03 
Arginine Amino acid 0.31 0.03 
Alpha-ketoglutarate Energy 0.31 0.03 
3-dehydrocarnitine Lipid 0.31 0.03 
Cyclo(phe-pro) Peptide 0.30 0.03 
1,6-anhydroglucose Carbohydrate 0.30 0.03 
2-aminoadipate Amino acid 0.30 0.03 
Arachidonate  Lipid 0.30 0.04 
2-aminobutyrate Amino acid 0.29 0.04 
Hypotaurine Amino acid 0.29 0.04 
Diphenhydramine Xenobiotics 0.28 0.05 
Hydrochlorothiazide Xenobiotics 0.28 0.05 
PD Epicatechin Xenobiotics -0.40 <0.01 
Beta-alanine Amino acid 0.38 0.01 
N-acetylgalactosamine Carbohydrate -0.38 0.01 
3-(4-hydroxyphenyl)lactate Amino acid -0.38 0.01 
3-phenylpropionate 
(hydrocinnamate) 
Amino acid -0.38 0.01 
Pipecolate Amino acid -0.37 0.01 
Glycerol Lipid -0.34 0.01 
Carnosine Peptide -0.34 0.02 
Cortisol Lipid -0.33 0.02 
5-aminovalerate Amino acid 0.33 0.02 
Citrulline Amino acid -0.33 0.02 
Glycerate Carbohydrate -0.32 0.02 
Isovalerate Lipid -0.32 0.03 
Aspartate Amino acid 0.31 0.03 
3-(4-hydroxyphenyl)propionate Amino acid -0.29 0.04 
2-hydroxybutyrate  Amino acid 0.28 0.05 
CAL Mannitol Carbohydrate -0.48 <0.01 
3-methylxanthine Xenobiotics -0.44 <0.01 
Dihomo-linolenate Lipid -0.44 <0.01 
Allantoin Nucleotide -0.42 <0.01 
3-phenylpropionate 
(hydrocinnamate) 
Amino acid -0.42 <0.01 
Fructose Carbohydrate -0.41 <0.01 
2-aminophenol Amino acid -0.41 <0.01 
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Beta-hydroxyisovalerate Amino acid -0.41 <0.01 
Pipecolate Amino acid -0.39 0.01 
Malate Energy -0.39 0.01 
Guanosine Nucleotide -0.36 0.01 
N-acetylgalactosamine Carbohydrate -0.35 0.01 
Ribitol Carbohydrate -0.34 0.01 
Glycine Amino acid -0.34 0.02 
Phosphoenolpyruvate  Carbohydrate 0.33 0.02 
Cyclo(phe-pro) Peptide -0.33 0.02 
N-carbamoylaspartate Amino acid -0.32 0.03 
Lactate Carbohydrate -0.32 0.03 
Threonylphenylalanine Peptide 0.32 0.03 
Caffeate Xenobiotics 0.31 0.03 
Carnitine Lipid -0.31 0.03 
Taurine Amino acid -0.30 0.03 
Cortisone Lipid -0.30 0.03 
Citrulline Amino acid -0.30 0.04 
Cortisol Lipid -0.30 0.04 
Guanine Nucleotide -0.29 0.04 
Glycerate Carbohydrate -0.29 0.04 
2-hydroxybutyrate  Amino acid 0.29 0.04 
Phenylalanylleucine Peptide 0.28 0.05 
Isovalerylcarnitine Amino acid 0.28 0.05 
Correlation coefficients were evaluated using covariance matrices to describe a correlation 
between mean changes in metabolites and changes in clinical indices at peak of induction (Day 
21). Correlations with p < 0.05 are reported in this table. FDR was applied to data; no 
metabolites with q < 0.05 were noted (data not reported). 
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FIGURE 1 – FLOW OF PATIENT RECRUITMENT 
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FIGURE 2.1 – MEAN PLAQUE INDEX DURING INDUCTION AND RESOLUTION OF 
EXPERIMENTAL SIBO 
Mean PI for stent side. General linear model used to compare Days 7–21 with baseline and Days 
35 and 49 with Day 21; p-value: *p<0.05, **p<0.001, †p<0.0001. 
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FIGURE 2.2 – MEAN GINGIVAL INDEX DURING INDUCTION AND RESOLUTION OF 
EXPERIMENTAL SIBO 
Mean GI for stent side. General linear model used to compare Days 7–21 with baseline and Days 
35 and 49 with Day 21; p-value: *p<0.05, **p<0.001, †p<0.0001. 
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FIGURE 2.3 – EXTENT BLEEDING ON PROBING DURING INDUCTION AND 
RESOLUTION OF EXPERIMENTAL SIBO 
Extent BOP for stent side. General linear model used to compare Days 7–21 with baseline and 
Days 35 and 49 with Day 21; p-value: *p<0.05, **p<0.001, †p<0.0001.  
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FIGURE 2.4 – MEAN PROBING DEPTH DURING INDUCTION AND RESOLUTION OF 
EXPERIMENTAL SIBO 
Mean PD for stent side. General linear model used to compare Days 7–21 with baseline and 
Days 35 and 49 with Day 21; p-value: *p<0.05. 
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FIGURE 2.5 – MEAN CLINICAL ATTACHMENT LEVEL DURING INDUCTION AND 
RESOLUTION OF EXPERIMENTAL SIBO 
Mean CAL for stent side. General linear model used to compare Days 7–21 with baseline and 
Days 35 and 49 with Day 21; no values reached statistical significance. 
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FIGURE 3 – OVERVIEW OF METABOLIC PATHWAYS  
49 
 
Metabolites that demonstrated statistically significant and trending changes in metabolites during 
experimental SIBO. Red circles indicate metabolites that demonstrated statistical significant 
decrease (applying FDR, q < 0.05) from baseline to peak of induction (Day 21) when samples 
were not stratified by BGI category (5-oxoproline, glutamate, histidine, serine, threonine, 
tyrosine). Blue circles indicate metabolites that demonstrated trending changes in each BGI 
category (unadjusted p < 0.05); 3-hydroxyisobutyrate demonstrated a trending decrease from 
baseline to peak of induction (Day 21) in BGI-H; 3-phenylpropionate demonstrated a trending 
increase from peak of induction (Day 21) to peak of resolution (Day 49) in BGI-P3; cis-
urocanate demonstrated a trending decrease from baseline to peak of induction (Day 21) in BGI-
P2 and a trending decrease from peak of induction (Day 21) to peak of resolution (Day 49) in 
BGI-P1; glutamine demonstrated a trending decrease from baseline to peak of induction (Day 
21) when samples were not stratified by BGI category; glycine demonstrated a trending increase 
from baseline to peak of induction (Day 21) and decrease from peak of induction (Day 21) to 
peak of resolution (Day 49) in BGI-G; homoserine demonstrated a trending decrease from 
baseline to peak of induction (Day 21) in BGI-G; hypotaurine demonstrated a trending decrease 
from baseline to peak of induction (Day 21) in BGI-H; isoleucine demonstrated a trending 
decrease from baseline to peak of induction (Day 21) and trending increase from peak of 
induction (Day 21) to peak of resolution (Day 49) in BGI-H; o-acetylhomoserine demonstrated a 
trending increase from peak of induction (Day 21) to peak of resolution (Day 49) in BGI-P3; 
phenylacetate demonstrated a trending decrease from peak of induction (Day 21) to peak of 
resolution (Day 49) in BGI-H; phenyllactate demonstrated a trending decrease from baseline to 
peak of induction (Day 21) in BGI-H and trending increase from peak of induction (Day 21) to 
peak of resolution (Day 49) in BGI-P1; taurine demonstrated a trending decrease from peak of 
induction (Day 21) to peak of resolution (Day 49) in BGI-H; tyramine demonstrated a trending 
decrease from peak of induction (Day 21) to peak of resolution (Day 49) in BGI-P3; valine 
demonstrated a trending decrease from baseline to peak of induction (Day 21) in BGI-H. 
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FIGURE 4 – SIMPLIFIED METABOLIC PATHWAYS 
a) Glutamine and glutamate metabolism sub-pathway 
b) Glycine, serine and threonine metabolism sub-pathway 
c) Histidine metabolism sub-pathway 
d) Glutathione metabolism sub-pathway 
Red indicates metabolites that demonstrated statistical significant decrease (applying FDR, q < 
0.05) from baseline to peak of induction (Day 21) when samples were not stratified by BGI 
category. Blue indicate metabolites that demonstrated trending changes in each BGI category 
(unadjusted p < 0.05): cis-urocanate demonstrated a trending decrease from baseline to peak of 
induction (Day 21) in BGI-P2 and a trending decrease from peak of induction (Day 21) to peak 
of resolution (Day 49) in BGI-P1; glutamine demonstrated a trending decrease from baseline to 
peak of induction (Day 21) when samples were not stratified by BGI category; glycine 
demonstrated a trending increase from baseline to peak of induction (Day 21) and decrease from 
peak of induction (Day 21) to peak of resolution (Day 49) in BGI-G; homoserine demonstrated a 
trending decrease from baseline to peak of induction (Day 21) in BGI-G, trans-urocanate 
demonstrated a trending decrease from peak of induction (Day 21) to peak of resolution (Day 49) 
without stratifying by BGI category.  
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APPENDIX 3.1.1 – EXTENDED DETAILS OF METHODS 
Analysis of salivary metabolome 
Metabolomic analyses were conducted at Metabolon, Inc. (Durham, NC). Saliva samples 
were extracted and prepared for analysis using the automated MicroLab STAR® (Hamilton 
Robotics). The extraction steps were optimized for removal of protein and maximum recovery of 
small molecules including both aqueous and organic soluble metabolites (Lee, New, & Ong, 
2003). Samples were placed briefly on a TurboVap® (Zymark) to remove the organic solvent. 
Each sample was then frozen and dried under vacuum. Samples were split into equal parts for 
analysis using GC/MS and LC/MS. Saliva samples were analyzed in duplicate from timepoints -
14, 0, 21 and 49 days for each subject. Samples were subjected to both non-targeted and targeted 
analysis via LC/MS and GC/MS. Results were reported as raw concentrations of metabolites for 
five groups (BGI-H, BGI-G, BGI-P1, P2, and P3) at seven time points (Day -14, 0, 7, 14, 21, 35 
and 49) which provided data at baseline, induction and resolution. All laboratory analyses were 
performed masked from sample, visit or patient information. 
 
LC/MS 
LC/MS was carried out using a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ 
mass spectrometer, which consisted of an electrospray ionization source and linear ion-trap mass 
analyzer. The sample extract was split into two aliquots, dried, then reconstituted in acidic or 
basic LC-compatible solvents, each of which contained 11 or more injection standards at fixed 
concentrations. One aliquot was analyzed using acidic positive ion optimized conditions and the 
other using basic negative ion optimized conditions in two independent injections using separate 
dedicated columns. Extracts reconstituted in acidic conditions were gradient eluted using water 
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and methanol both containing 0.1% formic acid, while the basic extracts, which also used 
water/methanol, contained 6.5mM ammonium bicarbonate. The MS analysis alternated between 
MS and data-dependent MS2 scans using dynamic exclusion.  
 
GC/MS 
The samples destined for GC/MS analysis were re-dried under vacuum desiccation for a 
minimum of 24 hours prior to being derivatized under dried nitrogen using bistrimethyl-silyl-
triflouroacetamide. The GC column was 5% phenyl and the temperature ramp is from 40° to 
300°C in a 16 minute period. Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-
scanning single-quadrupole mass spectrometer using electron impact ionization. The instrument 
was tuned and calibrated for mass resolution and mass accuracy on a daily basis. The 
information output from the raw data files was automatically extracted as discussed below. 
 
Accurate mass determination and MS/MS fragmentation (LC/MS), (LC/MS/MS) 
The LC/MS portion of the platform was based on a Waters ACQUITY UPLC and a 
Thermo-Finnigan LTQ-FT mass spectrometer, which had a linear ion-trap (LIT) front end and a 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer backend. For ions with 
counts greater than two million, an accurate mass measurement could be performed. Accurate 
mass measurements could be made on the parent ion as well as fragments. The typical mass error 
was less than 5 ppm. Ions with less than two million counts require a greater amount of effort to 
characterize. Fragmentation spectra (MS/MS) were typically generated in data dependent 
manner, but if necessary, targeted MS/MS could be employed, such as in the case of lower level 
signals. 
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Compound identification 
Compounds were identified by comparison to library entries of purified standards or 
recurrent unknown entities. Identification of known chemical entities was based on comparison 
to metabolomic library entries of purified standards. The combination of chromatographic 
properties and mass spectra gave an indication of a match to the specific compound or an 
isobaric entity. Additional entities could be identified by virtue of their recurrent nature (both 
chromatographic and mass spectral). These compounds have the potential to be identified by 
future acquisition of a matching purified standard or by classical structural analysis.  
 
Data normalization 
For studies spanning multiple days, a data normalization step was performed to correct 
variation resulting from instrument inter-day tuning differences. Each compound was corrected 
in run-day blocks by registering the medians to equal one and normalizing each data point 
proportionately. For studies that did not require more than one day of analysis, no normalization 
was necessary. 
 
Quality control 
Instrument variability was determined by calculating the median RSD for the internal 
standards that were added to each sample prior to injection into the mass spectrometers. Also 
included were several technical replicate samples created from a homogeneous pool containing a 
small amount of all study samples (“Client Matrix”). Overall process variability was determined 
by calculating the median RSD for all endogenous metabolites (i.e., non-instrument standards) 
present in 100% of the Client Matrix samples, which are technical replicates of pooled client 
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samples. Values for instrument and process variability associated with these samples met 
Metabolon’s acceptance criteria. Instrument variability for the internal standards had a median 
RSD of 5% and total process variability for the endogenous biochemicals had a median RSD of 
11% (APPENDIX 3.1.2). 
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APPENDIX 3.1.2 - INSTRUMENT AND PROCESS VARIABILITY.  
 
Quality control sample Measurement Median RSD 
Internal standards Instrument variability 5% 
Endogenous biochemicals Overall process variability 11% 
Internal standards were added into each study sample prior to injection into the MS instrument. 
Endogenous biochemicals from client matrix samples were technical replicates created from a 
small portion of experimental samples. 
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APPENDIX 3.2 – MEAN METABOLITE LEVELS DURING INDUCTION AND 
RESOLUTION OF EXPERIMENTAL SIBO BY BGI CATEGORY (N = 50; N = 10 PER BGI 
CATEGORY)  
BGI Metabolite 
Super-
pathway 
Baseline Day 21 Day 49 p-value*  p-value
†
 
H Panose Carbohydrate 0.38 0.25 0.28 <0.01 0.58 
Glycyltyrosine Peptide 0.45 0.27 0.34 <0.01 0.25 
Isobar: dihydrocaffeate, 
3,4-dihydroxycinnamate 
Xenobiotics 0.40 0.30 0.46 <0.01 0.01 
Pantothenate 
Cofactors and 
vitamins 
0.38 0.27 0.32 <0.01 0.38 
5,6-dihydrothymine Nucleotide 0.39 0.27 0.35 <0.01 0.13 
Hexaethylene glycol Xenobiotics 0.37 0.26 0.29 <0.01 0.40 
Histidine Amino acid 0.41 0.27 0.30 <0.01 0.48 
Deoxycarnitine Lipid 0.41 0.28 0.34 <0.01 0.08 
Vanillate Xenobiotics 0.29 0.21 0.24 <0.01 0.27 
Sucrose Carbohydrate 0.25 0.19 0.21 <0.01 0.32 
Glycerol 3-phosphate Lipid 0.33 0.20 0.30 <0.01 0.02 
Choline Lipid 0.41 0.20 0.26 <0.01 0.42 
Glycylleucine Peptide 0.36 0.25 0.30 <0.01 0.07 
3-(4-
hydroxyphenyl)lactate 
Amino acid 0.37 0.27 0.32 <0.01 0.08 
Uracil Nucleotide 0.57 0.22 0.30 <0.01 0.23 
Thymine Nucleotide 0.35 0.21 0.24 <0.01 0.35 
1,3-diaminopropane Amino acid 0.53 0.25 0.36 <0.01 0.10 
Fructose Carbohydrate 0.55 0.30 0.37 <0.01 0.37 
Glycine Amino acid 0.44 0.27 0.35 0.01 0.04 
Valine Amino acid 0.39 0.24 0.32 0.01 0.08 
Arginylleucine Peptide 0.41 0.23 0.35 0.01 0.11 
Linolenate  Lipid 0.39 0.16 0.19 0.01 0.55 
2,3-
dihydroxyisovalerate 
Cofactors and 
vitamins 
0.38 0.31 0.29 0.01 0.69 
Taurine Amino acid 0.41 0.31 0.31 0.01 0.92 
Nicotinate 
Cofactors and 
vitamins 
0.39 0.30 0.32 0.02 0.54 
5-oxoproline Amino acid 0.44 0.27 0.32 0.02 0.32 
Inosine Nucleotide 0.40 0.25 0.33 0.02 0.11 
Serylleucine Peptide 0.29 0.18 0.30 0.02 <0.01 
Theophylline Xenobiotics 0.38 0.25 0.32 0.03 0.23 
1,2-propanediol Lipid 0.40 0.16 0.29 0.03 0.24 
Cotinine Xenobiotics 0.42 0.24 0.31 0.03 0.08 
Alpha-ketoglutarate Energy 0.42 0.18 0.30 0.03 0.09 
Hypoxanthine Nucleotide 0.40 0.28 0.32 0.03 0.49 
Agmatine Amino acid 1.05 0.33 0.50 0.04 0.30 
Isoleucine Amino acid 0.38 0.28 0.36 0.04 0.02 
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Uridine Nucleotide 0.41 0.30 0.38 0.04 0.06 
3-hydroxyisobutyrate Amino acid 0.43 0.28 0.30 0.04 0.64 
Fumarate Energy 0.30 0.18 0.20 0.04 0.69 
Citramalate Amino acid 0.35 0.24 0.31 0.04 0.01 
5-aminovalerate Amino acid 0.40 0.32 0.37 0.04 0.17 
Sedoheptulose-7-
phosphate 
Carbohydrate 0.43 0.28 0.32 0.04 0.17 
Phenyllactate  Amino acid 0.58 0.33 0.43 0.04 0.27 
Tryptophan betaine  Amino acid 0.25 0.15 0.16 0.04 0.97 
Tryptophan Amino acid 0.37 0.24 0.30 0.04 0.21 
Arginylisoleucine Peptide 0.42 0.26 0.31 0.04 0.58 
P-cresol sulfate Amino acid 0.39 0.29 0.32 0.04 0.41 
Ricinoleic acid Xenobiotics 0.31 0.25 0.32 <0.05 0.06 
Aspartate Amino acid 0.33 0.20 0.27 <0.05 0.13 
Beta-alanine Amino acid 0.23 0.09 0.21 0.11 0.02 
Phenylacetate Amino acid 0.32 0.26 0.32 0.08 0.02 
Gallate Xenobiotics 0.30 0.23 0.28 0.09 0.04 
3,4-dihydroxybenzoate Xenobiotics 0.29 0.24 0.30 0.21 0.04 
Lactate Carbohydrate 0.22 0.12 0.24 0.14 0.04 
G 
  
  
  
  
  
  
 
 
Homoserine Amino acid 0.33 0.26 0.25 0.02 0.77 
Hippurate Xenobiotics 0.30 0.39 0.29 0.03 0.03 
Glycylleucine Peptide 0.27 0.34 0.30 0.03 0.12 
Phosphoethanolamine Lipid 0.31 0.37 0.28 0.13 <0.01 
Adenine Nucleotide 0.22 0.31 0.38 0.19 0.01 
Linolenate Lipid 0.24 0.19 0.11 0.22 0.02 
2-aminophenol Amino acid 0.32 0.31 0.23 0.79 0.03 
Glutamate Amino acid 0.41 0.38 0.14 0.67 0.04 
3-(2-
pyrrolidinyl)pyridine 
Xenobiotics 0.38 0.34 0.25 0.49 0.04 
Trans-4-hydroxyproline Amino acid 0.29 0.30 0.26 0.64 <0.05 
N-acetylputrescine Amino acid 0.35 0.37 0.22 0.87 <0.05 
P1 2-hydroxy-3-
methylvalerate 
Amino acid 0.29 0.22 0.36 0.02 0.02 
Creatine Amino acid 0.15 0.35 0.26 0.02 0.21 
5-oxoproline Amino acid 0.39 0.29 0.28 0.03 0.63 
Thymine Nucleotide 0.30 0.19 0.20 0.04 0.82 
3-aminoisobutyrate Nucleotide 0.13 0.22 0.17 0.04 0.22 
Epicatechin Xenobiotics 0.18 0.10 0.32 0.04 0.04 
Erythritol Xenobiotics 0.25 0.33 0.23 0.05 0.02 
Hypotaurine Amino acid 0.21 0.24 0.15 0.52 0.01 
Daidzein Xenobiotics 0.25 0.38 0.23 0.17 0.01 
Choline phosphate Lipid 0.32 0.34 0.22 0.84 0.01 
Alanylalanine Peptide 0.30 0.29 0.14 0.97 0.01 
Erythritol Xenobiotics 0.25 0.33 0.23 0.05 0.02 
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Xanthine Nucleotide 0.25 0.29 0.20 0.39 0.02 
Palmitoyl 
sphingomyelin 
Lipid 0.38 0.26 0.55 0.16 0.02 
Anserine Peptide 0.22 0.27 0.20 0.29 0.02 
Alpha-tocopherol 
Cofactors and 
vitamins 
0.23 0.26 0.17 0.58 0.03 
Beta-hydroxyisovalerate Amino acid 0.23 0.26 0.17 0.69 0.03 
Erythronate Carbohydrate 0.27 0.34 0.21 0.45 0.03 
Serylleucine Peptide 0.23 0.24 0.18 0.69 0.04 
Cis-urocanate Amino acid 0.29 0.28 0.23 0.70 0.04 
N-acetylmannosamine Carbohydrate 0.28 0.27 0.23 0.83 0.04 
Nicotinate 
Cofactors and 
vitamins 
0.30 0.28 0.25 0.58 0.04 
Serylisoleucine Peptide 0.32 0.34 0.19 0.70 0.04 
Nicotinamide 
Cofactors and 
vitamins 
0.16 0.18 0.12 0.64 0.05 
2,3-
dihydroxyisovalerate 
Cofactors and 
vitamins 
0.27 0.34 0.26 0.18 0.05 
Scyllo-inositol Lipid 0.26 0.32 0.26 0.17 0.05 
Phenyllactate  Amino acid 0.44 0.33 0.54 0.21 0.05 
Alpha-
hydroxyisocaproate 
Amino acid 0.15 0.20 0.13 0.38 0.05 
Deoxycarnitine Lipid 0.35 0.33 0.40 0.42 0.05 
P2 
Alpha-tocopherol 
Cofactors and 
vitamins 
0.41 0.26 0.44 <0.01 0.01 
Carnitine Lipid 0.35 0.16 0.23 <0.00 0.26 
2-aminophenol Amino acid 0.28 0.18 0.22 0.01 0.28 
Glycylproline Peptide 0.33 0.22 0.29 0.01 0.15 
Guanine Nucleotide 0.35 0.27 0.28 0.01 0.96 
Isoleucylisoleucine Peptide 0.17 0.24 0.18 0.01 0.21 
Tyrosylleucine Peptide 0.37 0.27 0.37 0.01 0.11 
Isobar: dihydrocaffeate, 
3,4-dihydroxycinnamate 
Xenobiotics 0.43 0.29 0.33 0.02 0.69 
12-HETE Lipid 0.28 0.14 0.23 0.03 0.07 
Cytidine diphosphate Nucleotide 0.36 0.27 0.36 0.03 0.07 
Sorbitol Carbohydrate 0.39 0.24 0.39 0.03 0.27 
Tryptophan betaine  Amino acid 0.29 0.23 0.31 0.03 0.07 
N-acetylmannosamine Carbohydrate 0.32 0.24 0.25 0.04 0.53 
Glucuronate Carbohydrate 0.33 0.26 0.32 0.04 0.17 
N-carbamoylaspartate Amino acid 0.45 0.35 0.40 <0.05 0.36 
Cis-urocanate Amino acid 0.33 0.18 0.28 <0.05 0.19 
Hypoxanthine Nucleotide 0.44 0.34 0.51 0.14 0.01 
Lysine Amino acid 0.47 0.37 0.52 0.12 0.01 
Uracil Nucleotide 0.35 0.35 0.45 0.94 0.01 
Pipecolate Amino acid 0.17 0.19 0.28 0.75 0.03 
4-methyl-2-
oxopentanoate 
Amino acid 0.27 0.26 0.19 0.86 0.03 
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N-acetylglycine Amino acid 0.36 0.30 0.40 0.13 0.04 
P3 Glucose-6-phosphate  Carbohydrate 0.46 0.32 0.33 0.02 0.87 
Arginylleucine Peptide 0.39 0.31 0.29 0.04 0.60 
3-hydroxyisobutyrate Amino acid 0.36 0.28 0.33 0.04 0.11 
Glycerate Carbohydrate 0.27 0.18 0.26 0.04 0.06 
Acetylcarnitine Lipid 0.32 0.27 0.29 0.04 0.29 
Deoxycarnitine Lipid 0.35 0.25 0.30 0.04 0.18 
Malate Energy 0.32 0.26 0.25 0.04 0.44 
Linolenate  Lipid 0.24 0.10 0.13 0.04 0.40 
Lignocerate  Lipid 0.38 0.31 0.35 0.04 0.10 
5-oxoproline Amino acid 0.43 0.28 0.36 <0.05 0.01 
Pinitol Lipid 0.19 0.13 0.24 0.38 0.01 
Sorbitol Carbohydrate 0.35 0.24 0.40 0.26 0.01 
2-
methylbutyroylcarnitine 
Amino acid 0.34 0.19 0.32 0.09 0.01 
Trans-4-hydroxyproline Amino acid 0.39 0.34 0.40 0.26 0.01 
Pseudoephedrine Xenobiotics 0.37 0.16 0.40 0.15 0.02 
Leucylalanine Peptide 0.31 0.33 0.30 0.22 0.02 
Adenine Nucleotide 0.29 0.22 0.36 0.30 0.02 
Adenosine 2'-
monophosphate  
Nucleotide 0.33 0.29 0.35 0.18 0.02 
3-(4-
hydroxyphenyl)lactate 
Amino acid 0.32 0.28 0.33 0.16 0.02 
O-acetylhomoserine Amino acid 0.25 0.18 0.29 0.24 0.03 
Cotinine Xenobiotics 0.39 0.28 0.37 0.07 0.03 
Arginylisoleucine Peptide 0.25 0.19 0.40 0.27 0.03 
Tyramine Amino acid 0.40 0.37 0.31 0.34 0.04 
3-phenylpropionate 
(hydrocinnamate) 
Amino acid 0.27 0.22 0.26 0.05 <0.05 
Isoleucylisoleucine Peptide 0.25 0.15 0.24 0.19 <0.05 
Log of mean metabolites reported as raw concentrations. * unadjusted p-values used to compare 
peak of induction (Day 21) with baseline; only metabolites with p < 0.05 reported. † unadjusted 
p-values used to compare peak of resolution (Day 49) with peak of induction (Day 21); only 
metabolites with p < 0.05 reported. Red values indicated decreased metabolite levels from 
baseline to peak of induction (Day 21) and from peak of induction (Day 21) to peak of resolution 
(Day 49). Blue values indicated increased metabolite levels from baseline to peak of induction 
(Day 21) and from peak of induction (Day 21) to peak of resolution (Day 49).  
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APPENDIX 3.3. CHANGES IN METABOLITES THAT CO-VARY WITH CHANGES IN 
CLINICAL INDICES AT PEAK OF INDUCTION BY BGI CATEGORY (N = 50 TOTAL; N = 
10 PER BGI CATEGORY) 
 
BGI 
Clinical 
Index 
Metabolite Super-pathway 
Correlation 
Coefficient 
p-
value 
q-
value 
H PI 4-hydroxyphenylacetate Amino acid 0.83 <0.01 0.44 
  
Glycylleucine Peptide 0.79 0.01 0.44 
  
Chlorogenate Xenobiotics 0.78 0.01 0.44 
  
Gallocatechin Xenobiotics 0.75 0.01 0.44 
  
O-acetylserine Amino acid 0.74 0.01 0.44 
  
3,4-dihydroxybenzoate Xenobiotics 0.73 0.02 0.44 
  
Cortisone Lipid 0.73 0.02 0.44 
  
2-oleoylglycerophosphoethanolamine Lipid 0.72 0.02 0.44 
  
Histidine Amino acid 0.71 0.02 0.44 
  
Isocaproate Lipid 0.71 0.02 0.44 
  
5,6-dihydrothymine Nucleotide 0.71 0.02 0.44 
  
glycerol 3-phosphate  Lipid 0.71 0.02 0.44 
  
Panose Carbohydrate -0.70 0.02 0.44 
  
2-hydroxyhippurate  Xenobiotics -0.70 0.02 0.44 
  
Glucosamine Carbohydrate 0.69 0.03 0.44 
  
Indolepropionate Amino acid 0.69 0.03 0.44 
  
5,6-dihydrouracil Nucleotide 0.69 0.03 0.44 
  
Adenine Nucleotide 0.66 0.04 0.50 
  
2-aminobutyrate Amino acid 0.66 0.04 0.50 
  
Creatine Amino acid 0.65 0.04 0.50 
  
3-phenylpropionate  Amino acid 0.65 0.04 0.50 
  
Saccharin Xenobiotics 0.65 0.04 0.50 
 
GI p-cresol sulfate Amino acid 0.84 <0.01 0.38 
  
Isocaproate Lipid 0.83 <0.01 0.38 
  
Glycerate Carbohydrate 0.81 <0.01 0.38 
  
7-methylxanthine Xenobiotics 0.77 0.01 0.50 
  
N-acetylaspartate Amino acid 0.77 0.01 0.50 
  
Leucylphenylalanine Peptide 0.76 0.01 0.50 
  
Pinitol Lipid 0.72 0.02 0.69 
  
Guanosine Nucleotide 0.69 0.03 0.69 
  
Histidine Amino acid 0.69 0.03 0.69 
  
Heptaethylene glycol Xenobiotics 0.69 0.03 0.69 
  
Creatine Amino acid 0.68 0.03 0.69 
  
3-phenylpropionate  Amino acid 0.67 0.04 0.71 
  
Caffeine Xenobiotics 0.67 0.04 0.71 
  
Leucylglycine Peptide 0.64 0.05 0.72 
  
Glucosamine Carbohydrate 0.63 0.05 0.72 
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BOP Butyrylcarnitine Lipid 0.75 0.01 0.72 
  
Saccharin Xenobiotics 0.73 0.02 0.72 
  
Gallocatechin Xenobiotics 0.71 0.02 0.72 
  
linolenate  Lipid 0.70 0.02 0.72 
  
Glycyltyrosine Peptide 0.70 0.03 0.72 
  
2-methylbutyroylcarnitine Amino acid 0.70 0.03 0.72 
  
Glutamate Amino acid 0.69 0.03 0.72 
  
Dihomo-linolenate Lipid -0.68 0.03 0.72 
  
Carnitine Lipid 0.67 0.04 0.72 
  
Alpha-hydroxyisovalerate Amino acid 0.66 0.04 0.72 
  
3-methyl-2-oxobutyrate Amino acid -0.65 0.04 0.72 
  
Glutamine Amino acid 0.64 0.04 0.72 
  
Mannitol Carbohydrate 0.64 0.05 0.72 
 
PD 5-aminovalerate Amino acid 0.86 <0.01 0.19 
  
Epicatechin Xenobiotics -0.84 <0.01 0.19 
  
1-kestose Xenobiotics -0.84 <0.01 0.19 
  
Glycerol Lipid -0.82 <0.01 0.19 
  
Arabinose Carbohydrate -0.80 0.01 0.19 
  
Gamma-aminobutyrate  Amino acid -0.80 0.01 0.19 
  
3-(4-hydroxyphenyl)propionate Amino acid -0.79 0.01 0.19 
  
N6-acetyllysine Amino acid -0.79 0.01 0.19 
  
Isovalerate Lipid -0.78 0.01 0.19 
  
N-acetylputrescine Amino acid -0.78 0.01 0.19 
  
Serylisoleucine Peptide 0.78 0.01 0.19 
  
Acetylsalicylate Xenobiotics -0.76 0.01 0.22 
  
Tryptophan Amino acid 0.75 0.01 0.23 
  
Trans-urocanate Amino acid -0.72 0.02 0.36 
  
Maltose Carbohydrate 0.68 0.03 0.53 
  
Hexaethylene glycol Xenobiotics -0.66 0.04 0.57 
  
Catechol sulfate Xenobiotics -0.66 0.04 0.57 
  
Hypoxanthine Nucleotide -0.64 0.04 0.63 
  
Chlorogenate Xenobiotics 0.64 0.05 0.63 
 
CAL 3-methylxanthine Xenobiotics -0.84 <0.01 0.46 
  
Carnitine Lipid -0.81 <0.01 0.46 
  
Sucralose Carbohydrate 0.78 0.01 0.46 
  
Serylleucine Peptide 0.77 0.01 0.46 
  
Cis-urocanate Amino acid -0.77 0.01 0.46 
  
Adenine Nucleotide -0.73 0.02 0.46 
  
Citrulline Amino acid -0.72 0.02 0.46 
  
Quinate Xenobiotics 0.70 0.02 0.46 
  
Naringenin Xenobiotics -0.70 0.02 0.46 
  
Chiro-inositol Lipid 0.70 0.02 0.46 
  
Mannitol Carbohydrate -0.70 0.03 0.46 
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13-methylmyristic acid Lipid -0.69 0.03 0.46 
  
Lignocerate (24:0) Lipid 0.69 0.03 0.46 
  
5,6-dihydrouracil Nucleotide -0.68 0.03 0.46 
  
Cyclo(phe-pro) Peptide -0.68 0.03 0.46 
  
Cinnamate Xenobiotics -0.68 0.03 0.46 
  
Glycyltyrosine Peptide -0.67 0.03 0.46 
  
Benzoate Xenobiotics -0.67 0.03 0.46 
  
Glycylleucine Peptide -0.66 0.04 0.46 
  
Glutarate  Amino acid 0.65 0.04 0.46 
  
3-(2-pyrrolidinyl)pyridine Xenobiotics -0.64 0.04 0.46 
  
Isoleucylisoleucine Peptide 0.64 0.05 0.46 
G PI 3-phosphoglycerate Carbohydrate 0.84 <0.01 0.45 
  
Sedoheptulose-7-phosphate Carbohydrate 0.82 <0.01 0.45 
  
Alpha-ketoglutarate Energy 0.77 0.01 0.66 
  
Beta-hydroxyisovalerate Amino acid 0.76 0.01 0.66 
  
Arachidonate (20:4n6) Lipid 0.73 0.02 0.73 
  
Pseudoephedrine Xenobiotics 0.72 0.02 0.73 
  
2-methylbutyroylcarnitine Amino acid 0.72 0.02 0.73 
  
Cyclo(phe-pro) Peptide 0.68 0.03 0.99 
  
3-phenylpropionate (hydrocinnamate) Amino acid 0.66 0.04 0.99 
 
GI Arachidonate (20:4n6) Lipid 0.87 <0.01 0.26 
  
2-methylbutyroylcarnitine Amino acid 0.80 0.01 0.75 
  
Stachydrine Xenobiotics 0.74 0.01 1.00 
  
Benzoylecgonine Xenobiotics 0.72 0.02 1.00 
  
5,6-dihydrouracil Nucleotide 0.71 0.02 1.00 
  
Fructose Carbohydrate 0.69 0.03 1.00 
  
3-methyl-2-oxobutyrate Amino acid -0.67 0.03 1.00 
  
Lysylleucine Peptide 0.64 0.04 1.00 
  
Lathosterol Lipid 0.64 0.05 1.00 
  
Alpha-ketoglutarate Energy 0.64 0.05 1.00 
 
BOP Guanidine Nucleotide 0.88 <0.01 0.18 
  
Threitol Carbohydrate 0.85 <0.01 0.26 
  
Gallate Xenobiotics 0.82 <0.01 0.26 
  
Salicylate Xenobiotics -0.80 0.01 0.26 
  
Gallocatechin Xenobiotics 0.78 0.01 0.26 
  
Leucylalanine Peptide 0.78 0.01 0.26 
  
Cadaverine Amino acid 0.77 0.01 0.26 
  
Fucose Carbohydrate 0.77 0.01 0.26 
  
Glutamine Amino acid 0.77 0.01 0.26 
  
Benzoate Xenobiotics 0.76 0.01 0.28 
  
Choline Lipid 0.75 0.01 0.28 
  
Threonylphenylalanine Peptide 0.74 0.01 0.30 
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Glycylleucine Peptide 0.74 0.02 0.30 
  
Sucrose Carbohydrate 0.73 0.02 0.32 
  
p-cresol sulfate Amino acid 0.71 0.02 0.36 
  
Cortisone Lipid -0.69 0.03 0.36 
  
Cis-urocanate Amino acid 0.69 0.03 0.36 
  
Phenylalanylleucine Peptide 0.69 0.03 0.36 
  
Tryptophan Amino acid 0.69 0.03 0.36 
  
Linoleate (18:2n6) Lipid -0.69 0.03 0.36 
  
Arginylisoleucine Peptide 0.68 0.03 0.36 
  
Leucylglycine Peptide -0.68 0.03 0.37 
  
Cinnamate Xenobiotics 0.67 0.03 0.37 
  
Trans-4-hydroxyproline Amino acid 0.66 0.04 0.38 
  
Deoxycarnitine Lipid 0.66 0.04 0.38 
  
Phenylalanine Amino acid 0.66 0.04 0.38 
  
Choline phosphate Lipid 0.66 0.04 0.38 
  
N1-Methyl-2-pyridone-5-
carboxamide 
Cofactors and 
vitamins 
0.64 0.05 0.41 
  
Isovalerylcarnitine Amino acid 0.64 0.05 0.41 
 
PD 3-(4-hydroxyphenyl)propionate Amino acid 0.83 <0.01 0.41 
  
N-acetylputrescine Amino acid 0.83 <0.01 0.41 
  
Citrulline Amino acid -0.79 0.01 0.44 
  
Aspartame Xenobiotics -0.76 0.01 0.44 
  
2-hydroxybutyrate (AHB) Amino acid 0.75 0.01 0.44 
  
Glucosamine Carbohydrate 0.75 0.01 0.44 
  
3-(4-hydroxyphenyl)lactate Amino acid -0.74 0.01 0.44 
  
Beta-alanine Amino acid 0.74 0.01 0.44 
  
3-phenylpropionate (hydrocinnamate) Amino acid -0.73 0.02 0.46 
  
Lactate Carbohydrate -0.69 0.03 0.65 
  
Pyroglutamine Amino acid 0.69 0.03 0.65 
  
N-acetylglycine Amino acid -0.65 0.04 0.74 
  
Beta-hydroxyisovalerate Amino acid -0.64 0.04 0.74 
  
1,6-anhydroglucose Carbohydrate -0.64 0.05 0.74 
  
Isoleucylisoleucine Peptide -0.64 0.05 0.74 
  
Ethanolamine Lipid 0.64 0.05 0.74 
 
CAL Allantoin Nucleotide -0.80 0.01 0.46 
  
2-hydroxy-3-methylvalerate Amino acid 0.78 0.01 0.46 
  
3-(2-pyrrolidinyl)pyridine Xenobiotics 0.78 0.01 0.46 
  
4-methyl-2-oxopentanoate Amino acid 0.78 0.01 0.46 
  
Diphenhydramine Xenobiotics 0.77 0.01 0.47 
  
1,6-anhydroglucose Carbohydrate -0.73 0.02 0.71 
  
Pipecolate Amino acid -0.71 0.02 0.71 
  
Heptaethylene glycol Xenobiotics 0.71 0.02 0.71 
  
Trans-urocanate Amino acid 0.68 0.03 0.71 
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Aspartame Xenobiotics -0.67 0.03 0.71 
  
2-hydroxybutyrate  Amino acid 0.67 0.03 0.71 
  
Cortisone Lipid -0.66 0.04 0.71 
  
Glycerate Carbohydrate -0.66 0.04 0.71 
  
N-acetylputrescine Amino acid 0.65 0.04 0.71 
  
4-hydroxy-3-methoxybenzyl alcohol Xenobiotics -0.64 0.05 0.71 
P1 PI 3-phosphoglycerate Carbohydrate 0.71 0.02 0.96 
 
GI 2-aminoadipate Amino acid -0.67 0.03 1.00 
  
Cysteine Amino acid -0.66 0.04 1.00 
  
3-aminoisobutyrate Nucleotide 0.64 0.05 1.00 
 
BOP 3-aminoisobutyrate Nucleotide 0.92 <0.01 0.03* 
  
1,3-diaminopropane Amino acid 0.91 <0.01 0.03* 
  
6'-sialyllactose Carbohydrate -0.80 0.01 0.50 
  
2-aminophenol Amino acid 0.78 0.01 0.51 
  
Arabinose Carbohydrate 0.76 0.01 0.58 
  
Cysteine Amino acid -0.74 0.01 0.59 
  
Glucose Carbohydrate -0.69 0.03 0.98 
 
PD Naringenin Xenobiotics 0.87 <0.01 0.26 
  
Cyclo(phe-pro) Peptide 0.77 0.01 0.76 
  
Triethanolamine Xenobiotics 0.77 0.01 0.76 
  
Indolepropionate Amino acid 0.74 0.02 0.82 
  
Phenol sulfate Amino acid 0.70 0.02 0.82 
  
Phenylalanylisoleucine Peptide -0.65 0.04 0.82 
  
Phosphoethanolamine Lipid 0.64 0.05 0.82 
 
CAL 3-methylxanthine Xenobiotics -0.70 0.02 0.90 
  
Glycerol Lipid -0.67 0.03 0.90 
  
Pantothenate 
Cofactors and 
vitamins 
-0.65 0.04 0.90 
  
Lidocaine Xenobiotics 0.64 0.05 0.90 
P2 PI Catechol sulfate Xenobiotics 0.76 0.01 0.43 
  
5-aminovalerate Amino acid -0.75 0.01 0.43 
  
3-(2-pyrrolidinyl)pyridine Xenobiotics 0.74 0.02 0.43 
  
Alpha-hydroxyisocaproate Amino acid 0.72 0.02 0.43 
  
Isoleucylserine Peptide -0.71 0.02 0.43 
  
1,2-propanediol Lipid 0.70 0.02 0.43 
  
3-methyl-2-oxobutyrate Amino acid 0.70 0.02 0.43 
  
1-palmitoylplasmenylethanolamine Lipid 0.69 0.03 0.43 
  
5-oxoproline Amino acid 0.69 0.03 0.43 
  
1,3-diaminopropane Amino acid 0.69 0.03 0.43 
  
1,5-anhydroglucitol (1,5-AG) Carbohydrate 0.69 0.03 0.43 
  
2-hydroxy-3-methylvalerate Amino acid 0.69 0.03 0.43 
  
3-dehydrocarnitine Lipid 0.69 0.03 0.43 
  
12-HETE Lipid 0.69 0.03 0.43 
65 
 
  
1,6-anhydroglucose Carbohydrate 0.69 0.03 0.43 
  
2-hydroxyglutarate Lipid 0.69 0.03 0.43 
  
Arginine Amino acid 0.68 0.03 0.43 
  
4-acetamidophenol Xenobiotics 0.68 0.03 0.43 
  
Citrate Energy 0.67 0.03 0.43 
  
3-(4-hydroxyphenyl)lactate Amino acid -0.67 0.03 0.43 
  
Mannitol Carbohydrate 0.66 0.04 0.44 
  
1-kestose Xenobiotics -0.66 0.04 0.44 
  
2-aminoadipate Amino acid 0.66 0.04 0.44 
  
Glycyltyrosine Peptide -0.65 0.04 0.44 
  
3-aminoisobutyrate Nucleotide 0.64 0.05 0.45 
  
2-aminophenol Amino acid 0.64 0.05 0.45 
 
GI 3-(4-hydroxyphenyl)lactate Amino acid -0.67 0.04 0.98 
 
BOP 5,6-dihydrothymine Nucleotide -0.76 0.01 0.88 
  
Phenylalanine Amino acid 0.75 0.01 0.88 
  
Cotinine Xenobiotics -0.74 0.02 0.88 
  
Isovalerate Lipid -0.73 0.02 0.88 
  
Tryptophan Amino acid -0.72 0.02 0.88 
  
Adenosine 2'-monophosphate Nucleotide -0.71 0.02 0.88 
  
Histamine Amino acid -0.70 0.02 0.88 
  
2-hydroxybutyrate Amino acid -0.68 0.03 0.92 
  
5-aminovalerate Amino acid -0.66 0.04 0.92 
  
N-carbamoylaspartate Amino acid -0.63 0.05 0.92 
  
7-methylxanthine Xenobiotics -0.63 0.05 0.92 
 
PD Pentaethylene glycol Xenobiotics -0.88 <0.01 0.21 
  
Carnitine Lipid -0.85 <0.01 0.21 
  
Alpha-hydroxyisocaproate Amino acid 0.81 <0.01 0.35 
  
Glycyltyrosine Peptide -0.75 0.01 0.78 
  
3-(4-hydroxyphenyl)lactate Amino acid -0.70 0.02 0.78 
  
Heptaethylene glycol Xenobiotics -0.69 0.03 0.78 
  
Catechol sulfate Xenobiotics 0.68 0.03 0.78 
  
Isocaproate Lipid -0.68 0.03 0.78 
  
Cyclo(leu-pro) Peptide -0.65 0.04 0.78 
  
1-kestose Xenobiotics -0.65 0.04 0.78 
  
3-methylxanthine Xenobiotics -0.64 0.05 0.78 
 
CAL Phenol sulfate Amino acid 0.85 <0.01 0.30 
  
Glutathione, oxidized  Amino acid -0.82 <0.01 0.30 
  
Beta-hydroxyisovalerate Amino acid 0.81 <0.01 0.30 
  
Linoleate (18:2n6) Lipid -0.81 <0.01 0.30 
  
Isovalerate Lipid -0.78 0.01 0.36 
  
adenosine 2'-monophosphate Nucleotide -0.77 0.01 0.36 
  
2-aminobutyrate Amino acid -0.72 0.02 0.54 
  
Glucosamine Carbohydrate -0.72 0.02 0.54 
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Adenosine 5'-monophosphate  Nucleotide -0.71 0.02 0.54 
  
7-methylxanthine Xenobiotics -0.71 0.02 0.54 
  
Saccharin Xenobiotics -0.69 0.03 0.54 
  
Glucose-6-phosphate  Carbohydrate -0.68 0.03 0.54 
  
Galactose Carbohydrate -0.68 0.03 0.54 
  
Phenylalanylisoleucine Peptide -0.68 0.03 0.54 
  
Allantoin Nucleotide -0.68 0.03 0.54 
  
3,4-dihydroxybenzoate Xenobiotics -0.66 0.04 0.59 
  
Ccytidine diphosphate Nucleotide 0.64 0.05 0.59 
  
Phosphoenolpyruvate  Carbohydrate 0.64 0.05 0.59 
  
Lysine Amino acid -0.64 0.05 0.59 
P3 PI Fructose-6-phosphate Carbohydrate 0.80 0.01 0.85 
  
Pyruvate Carbohydrate -0.74 0.02 0.85 
  
2,3-dihydroxyisovalerate 
Cofactors and 
vitamins 
0.72 0.02 0.85 
  
N-acetylglycine Amino acid 0.71 0.02 0.85 
  
Glycyltyrosine Peptide 0.65 0.04 0.85 
  
Adenosine 5'-monophosphate  Nucleotide 0.64 0.05 0.85 
  
Acetylcarnitine Lipid -0.64 0.05 0.85 
 
GI Sorbitol Carbohydrate -0.76 0.01 0.99 
  
Scyllo-inositol Lipid 0.66 0.04 0.99 
 
BOP Isoleucylisoleucine Peptide -0.83 <0.01 0.68 
  
Hydrochlorothiazide Xenobiotics 0.80 0.01 0.73 
  
Palmitoyl sphingomyelin Lipid 0.73 0.02 0.77 
  
Isovalerylcarnitine Amino acid -0.72 0.02 0.77 
  
Linolenate  Lipid -0.71 0.02 0.77 
  
Threonine Amino acid 0.68 0.03 0.77 
  
Heptaethylene glycol Xenobiotics 0.67 0.03 0.77 
  
Ethanolamine Lipid -0.66 0.04 0.77 
  
5,6-dihydrothymine Nucleotide 0.66 0.04 0.77 
  
Lignocerate  Lipid 0.65 0.04 0.77 
  
3-(2-pyrrolidinyl)pyridine Xenobiotics -0.65 0.04 0.77 
  
Trans-4-hydroxyproline Amino acid -0.64 0.04 0.77 
  
Isoleucylserine Peptide 0.64 0.05 0.77 
  
Linoleate  Lipid -0.64 0.05 0.77 
 
PD 1-palmitoylplasmenylethanolamine Lipid -0.85 <0.01 0.15 
  
Lysine Amino acid -0.85 <0.01 0.15 
  
Carnitine Lipid -0.82 <0.01 0.15 
  
N-acetylaspartate  Amino acid 0.80 0.01 0.15 
  
Thymine Nucleotide -0.80 0.01 0.15 
  
Fructose Carbohydrate -0.79 0.01 0.15 
  
Betaine Amino acid -0.79 0.01 0.15 
  
Allantoin Nucleotide -0.78 0.01 0.15 
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13-methylmyristic acid Lipid -0.77 0.01 0.15 
  
Glucose Carbohydrate -0.77 0.01 0.15 
  
12-HETE Lipid -0.77 0.01 0.15 
  
Glycerol Lipid -0.77 0.01 0.15 
  
4-methyl-2-oxopentanoate Amino acid -0.77 0.01 0.15 
  
Phenyllactate  Amino acid -0.77 0.01 0.15 
  
Arabitol Carbohydrate 0.77 0.01 0.15 
  
Pentaethylene glycol Xenobiotics -0.77 0.01 0.15 
  
Adenine Nucleotide -0.76 0.01 0.16 
  
Mannitol Carbohydrate -0.75 0.01 0.16 
  
Leucylglycine Peptide -0.75 0.01 0.16 
  
Leucylalanine Peptide 0.75 0.01 0.16 
  
Homoserine Amino acid -0.74 0.01 0.16 
  
Diphenhydramine Xenobiotics -0.74 0.01 0.16 
  
Arginine Amino acid -0.74 0.01 0.16 
  
Phenylalanine Amino acid 0.74 0.02 0.16 
  
Isovalerate Lipid -0.74 0.02 0.16 
  
Caffeine Xenobiotics 0.73 0.02 0.17 
  
Hypotaurine Amino acid -0.72 0.02 0.18 
  
Cortisone Lipid -0.72 0.02 0.18 
  
3-(4-hydroxyphenyl)propionate Amino acid -0.71 0.02 0.18 
  
4-acetamidophenol Xenobiotics -0.71 0.02 0.18 
  
Lactate Carbohydrate -0.70 0.02 0.20 
  
Malate Energy -0.70 0.03 0.20 
  
Erythronate Carbohydrate -0.70 0.03 0.20 
  
Glycerate Carbohydrate -0.69 0.03 0.20 
  
Salicylate Xenobiotics -0.69 0.03 0.21 
  
O-acetylhomoserine Amino acid 0.68 0.03 0.21 
  
Ribulose Carbohydrate 0.68 0.03 0.21 
  
Beta-alanine Amino acid -0.68 0.03 0.21 
  
7-methylxanthine Xenobiotics -0.67 0.03 0.21 
  
Glutathione, oxidized Amino acid -0.67 0.04 0.22 
  
Taurine Amino acid -0.66 0.04 0.22 
  
Cadaverine Amino acid 0.66 0.04 0.22 
  
Trigonelline (N'-methylnicotinate) 
Cofactors and 
vitamins 
-0.66 0.04 0.22 
  
Leucylphenylalanine Peptide -0.66 0.04 0.22 
  
Citrulline Amino acid -0.66 0.04 0.22 
  
3-dehydrocarnitine Lipid -0.65 0.04 0.22 
  
Glucosamine Carbohydrate 0.64 0.05 0.24 
  
Phenylalanylleucine Peptide 0.64 0.05 0.24 
  
Chlorogenate Xenobiotics 0.64 0.05 0.24 
  
Ribitol Carbohydrate -0.64 0.05 0.24 
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 CAL N-acetylgalactosamine Carbohydrate -0.89 <0.01 0.15 
  
Dihomo-linolenate (20:3n3 or n6) Lipid -0.86 <0.01 0.16 
  
Guanine Nucleotide -0.84 <0.01 0.19 
  
Alpha-tocopherol acetate 
Cofactors and 
vitamins 
-0.72 0.02 0.67 
  
Isoleucylisoleucine Peptide 0.71 0.02 0.67 
  
Cyclo(leu-pro) Peptide -0.71 0.02 0.67 
  
2-aminophenol Amino acid -0.70 0.02 0.67 
  
4-hydroxyphenylacetate Amino acid -0.69 0.03 0.67 
  
Sucralose Carbohydrate -0.69 0.03 0.67 
  
3-methyl-2-oxovalerate Amino acid -0.68 0.03 0.67 
  
4-hydroxy-3-methoxybenzyl alcohol Xenobiotics -0.68 0.03 0.67 
  
Pyridoxate 
Cofactors and 
vitamins 
-0.68 0.03 0.67 
  
3-phosphoglycerate Carbohydrate -0.64 0.05 0.87 
  
Threonate 
Cofactors and 
vitamins 
0.64 0.05 0.87 
Correlation coefficients were evaluated using covariance matrices to describe a correlation 
between changes in metabolites and changes in clinical indices by BGI category at peak of 
induction (Day 21). Correlations with p < 0.05 are reported in this table. *FDR-adjusted p-values 
(q<0.05). 
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